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1 Introduction 
1.1 The genome is exposed to DNA-damaging agents 
The genomes of all life forms are constantly exposed to DNA-damaging agents such as 
background ionizing radiation (IR), ultraviolet light (UV), and free oxygen radicals 
(Hoeijmakers, 2001). Medical diagnostic methods like radiographs or CT scans, and 
therapeutic strategies like chemotherapy and radiotherapy increase the exposure of humans to 
genotoxins. Exposure to genotoxins results in DNA damage. If not repaired, DNA lesions may 
be replicated during S phase or segregated into daughter cells during cell division, thus 
irreversibly establishing mutations in the individuals genome (Pages and Fuchs, 2002). 
Mutations may induce malignant transformation of single cell clones and cancer development 
(Bishop, 1991). Cells have therefore evolved mechanisms to accurately respond to DNA 
damage. When DNA is damaged, cells mount a well orchestrated response that includes cell 
cycle arrest and activation of DNA repair, thus promoting stability of the genome (Elledge, 
1996; Weinert, 1998; Longhese, 1998). Genetic defects within these protection mechanisms 
may dramatically increase the rate of mutation, promoting genomic instability and the process 
of carcinogenesis (Hoeijmakers, 2001).  
 
1.2 Genomic instability is an important factor in carcinogenesis 
 Genomic instability is now accepted as an important factor of carcinogenesis. It is 
defined as abnormal accumulation of mutations and cytogenetic alterations (Morgan et al., 
1996; Hartwell, 1992). Nowell first suggested that genomic instability could initiate cancer 
development by promoting the evolution of increasingly abnormal tumor subpopulations 
(Nowell, 1976). The latter identification of oncogenes and tumor suppressor genes has 
demonstrated that single genetic defects may indeed trigger and even cause cancer (Hunter, 
1991; Marshall, 1991). In support of Nowell’s hypothesis, a sequential order of specific 
mutations has been described for several human tumors. Colorectal carcinomas, for example, 
typically exhibit inactivating mutations within the APC tumor suppressor gene followed by 
activating mutations of the K-Ras oncogene, loss of the active DCC tumor suppressor gene 
and finally the loss of functional p53 (Fearon and Vogelstein, 1990). Because the inactivation 
of tumor suppressor genes (APC, DCC, p53) requires mutation of both alleles, at least seven 
mutations must take place for the colorectal cancer to develop. Similar sequential genetic 
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alterations were reported for lymphocytic cancers, malignant melanoma, and small cell lung 
cancer (Christians et al., 1995). Loeb validated Nowell’s hypothesis showing that a normal cell 
endures no more than 2-3 mutations in an average life span, which can not account for the 6-7 
mutations that are statistically required to set off malignant proliferation. He postulated that 
early in carcinogenesis mutations in key genes providing proper functions of DNA metabolism 
such as DNA repair, segregation, replication, and cell cycle control arise that increase the 
acquisition rate of spontaneous mutations, suggesting that cancer is a genetic multi-step 
disease (Loeb, 1991). Taken together, these studies suggest that defects in genes that ensure 
accurate DNA metabolism and provide genomic stability play a key role in cancer 
development. 
 
 Given that genomic instability is a central driving force behind malignant 
transformation, there has been significant interest in determining the molecular mechanisms 
that maintain genomic stability. Studies in yeast revealed different classes of genetic defects 
that lead to genomic instability. These include defects in DNA repair genes as well as in 
checkpoint control genes (Hartwell, 1992; Kaufmann et al., 1997), suggesting that these are 
the two key mechanisms in prevention of genomic instability and cancer.  
 
1.3 Defects in DNA repair mechanisms cause genomic instability 
 The most evident class of DNA damage response mechanisms expected to influence 
genetic stability are DNA repair mechanisms. Different repair systems constantly scan the 
DNA to localize and repair specific types of DNA damage (Yu, 1999; Rosen, 1999; Lindahl 
and Wood, 1999). UV-induced thymidine-dimers, for example, are mainly repaired by excision 
repair (Sancar, 1994). Mismatches induced by polymerases can be readily repaired by DNA 
mismatch repair (Peltomaki, 2001; Hsieh, 2001). However, repair of DNA double strand 
breaks is less well understood. These breaks can be repaired with high fidelity by homologous 
recombination pathways and by error prone non-homologous end-joining pathways. Until 
recently, mammalian cells were thought to rely predominantly on non-homologous repair 
mechanisms; however, recent work has now shown that homologous repair also occurs 
(Jackson, 2002). It is evident that defects within these repair mechanisms influence genome 
stability. It has been postulated that defects in repair genes may generate an increased rate of 
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overall mutations and, as a result, an elevated probability of oncogenic mutations (Loeb, 1991; 
Hoeijmakers, 2001). This hypothesis has been repeatedly verified. 
 
1.3.1 Xeroderma pigmentosum 
 The hereditary instability syndrome Xeroderma pigmentosum (XP) provides proof for 
repair genes being beneficial for maintenance of genomic stability. This autosomal-recessive 
disease is characterized by hypersensitivity to UV light and an early onset of cutaneous 
malignancies (malignant melanoma, basal cell and squamous cell carcinoma). Several genes 
identifying individual XP loci have been cloned. Defects within these genes generally impair the 
initial steps of nucleotide excision repair (de Boer and Hoeijmakers, 2000; Wood, 1995). 
Hence, a gene defect and subsequent dysfunction of a specific DNA repair mechanism trigger 
the accumulation of mutations and ultimately the development of cancer. 
 
1.3.2 Nijmegen breakage syndrome 
 Studies on the inherited disorder Nijmegen breakage syndrome (NBS) validated the 
findings gained from XP. NBS patients exhibit microcephaly, immunodeficiency, and a higher 
incidence of hematopoietic malignancy. Cells derived from NBS patients are more sensitive to 
IR and display higher levels of spontaneous and induced chromosomal instability (Weemaes et 
al., 1981; van der Burgt et al., 1996). NBS cells also fail to induce G1-S and S phase cell cycle 
arrest that usually follows DNA damage (Tauchi et al., 2002). The disease NBS is caused by 
genetic defects in the NBS1 gene, which was mapped to the gene locus encoding the protein 
p95 (Varon et al., 1998). p95 was shown to be one of five molecules of a DNA double-strand 
break repair complex. The function of the repair complex is impaired in cells from NBS 
patients, which strongly suggests that dysfunction of a DNA repair mechanism causes genomic 
instability and cancer predisposition (Petrini et al., 1997). The fact that defects in a gene 
required for DNA repair also lead to defects in DNA damage-induced cell cycle arrest, 
suggests that these two mechanisms functionally overlap or operate in close functional 
proximity. 
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1.3.3 BRCA1 
 Women with germ-line mutations of the BRCA1 gene exhibit predisposition to breast 
and ovarian cancers (Feunteun and Lenoir, 1996). This suggests an impact of the BRCA1 gene 
product in maintenance of genomic integrity. However, it was not clear what role BRCA1 
played in this process. A role in DNA repair has been proposed, but BRCA1 has also been 
involved in cell cycle control (Paterson, 1998; Xu et al., 1999). Both functions would suffice 
individually to explain the carcinogenic effect of BRCA1 mutations. Although it remains 
unclear whether BRCA1’s role in DNA repair or its role in cell cycle control or a combination 
of the two is responsible for the elevated risk of cancer, these studies suggest that disruption of 
DNA damage-activated cell cycle arrest and/or DNA repair leads to increased cancer 
susceptibility.  
 
1.4 Cell cycle checkpoints also have an impact on genomic 
stability 
 In view of their apparent participation in DNA damage responses, DNA damage-
induced cell cycle arrest pathways gained importance in cancer research (Hartwell and Kastan, 
1994). During proliferation, every eucaryotic cell replicates DNA and divides in a series of 
coordinated events that constitute the cell cycle (G1 to S to G2 to M). Cell cycle progression 
is carried out by a cascade of protein phosphorylations mediated by cyclin-dependent kinases 
(CDKs). At each cell cycle boundary, e.g., G1-S or G2-M, CDKs associate with their 
corresponding, transiently expressed cyclins. The active cyclin-CDK complex then relays the 
cell to the next stage of the cell cycle (Collins et al., 1997). If the conditions for transition are 
not appropriate, signaling cascades are activated that inhibit CDK function. This delays 
progression through the cell cycle until the disturbance has been cleared, ensuring fidelity of 
previous cell cycle events. Referring to their supervisory function, these signaling cascades 
were termed cell cycle checkpoints (Hartwell and Weinert, 1989). In a model, checkpoints 
consist of a sensor that detects irregularities and a signaling cascade that enhances and 
transmits the signal to an effector. The effector then relays the signal to the cell cycle 
machinery to delay cell cycle progression (Carr, 1996; Weinert, 1997; Fig. A). 
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Figure A. Genotoxins induce DNA damage, which activates cellular signaling cascades consisting of 
sensor(s), signal(s), and effector(s). These signaling pathways mediate the cellular DNA damage 
response. While checkpoint activation leads to cell cycle arrest, parallel pathways initiate DNA repair.  
 
 
 Today, at least four different checkpoints are known that monitor DNA metabolism in 
eucaryotes: The G1-S checkpoint halts the cell at the G1-S transition. The S-phase progression 
checkpoint slows down progression through S-phase. The G2-M checkpoint and the S/M 
checkpoint prevent segregation of damaged or incompletely replicated DNA (Weinert, 1998; 
Elledge, 1996). DNA damage checkpoints thus form part of the cellular DNA damage 
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response helping to preserve the integrity of the genome and promote genomic stability (Fig. 
B).  
 
 
Figure B. The somatic cell cycle is defined by the period between two mitotic events. It is divided into 
M-phase, G1-phase, S-phase, and G2-phase. If DNA damage is detected, signal-transduction pathways 
lead to checkpoint activation. At least four different checkpoints monitor DNA metabolism in 
eucaryotes: The G1-S checkpoint, the S-phase progression checkpoint, the G2-M checkpoint, and the 
S/M checkpoint. 
 
 As cell cycle checkpoints are not essential for cell survival their significance for 
genomic stability has been less apparent. The impact of checkpoint defects, however, may be 
all the more: genetic defects in checkpoint-regulating genes may disrupt checkpoint activation 
in response to altered DNA metabolism. Depending upon the localization of the defect, various 
types of damage are to be expected: override of the G1-S checkpoint, for example, would 
generate mutations as a consequence of premature DNA replication. Loss of the G2-M 
checkpoint would result in gross chromosomal aberrations and loss of genetic material. Any 
DNA damage responsive checkpoint gene deficiency in combination with induced DNA 
damage, e.g., by IR would result in an elevation of mutagenic events in a cell. These notions 
support an implication of genetic checkpoint defects in genomic instability and cancer 
development. Interestingly, unlike normal cells, tumor cells often exhibit checkpoint defects 
when exposed to DNA damage (Hartwell et al., 1994). Although we know little about how 
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these checkpoints function in humans, their impact on genomic stability and their association 
with cancer underscore the importance of studying these mechanisms intensively.  
 
1.4.1 p53 
 There is increasing evidence that tumor suppressor genes encode proteins that regulate 
cell cycle control mechanisms (Collins et al., 1997). As a result, the first breakthroughs in the 
search for checkpoint genes causing genomic instability were achieved by the analysis of 
known tumor suppressor genes. The most prominent discovery was the tumor suppressor gene 
p53. p53 is a sequence specific DNA-binding transcriptional activator (Levine, 1997). It up-
regulates expression of several genes involved in either G1 arrest or apoptosis. DNA damage 
or inappropriate growth stabilize p53 metabolically and consequently increase cellular p53 
levels (Donehower, 1997). p53-dependent genes then mediate cell cycle delay at the G1-S 
transition or, alternatively, induce apoptosis (Kastan et al., 1995).  
 
 Effects of defective p53 have been studied in the familial cancer syndrome Li-Fraumeni 
(LF). This autosomal-recessive disease is caused by homozygous p53 mutations. LF patients 
exhibit an early onset of multiple primary tumors, indicating that functional inactivation of p53 
plays a significant role in tumorigenesis (Tainsky et al., 1995). Knock out mice with a 
homozygous p53-null mutation are viable, and like LF patients exhibit cancer development 
very early in life (Donehower et al., 1997). On a cellular level, p53-deficiency (p53-) inhibits 
initiation of the G1 checkpoint following DNA damage, and p53-deficient cells are unable to 
undergo apoptosis in response to irreparable DNA damage. Lack of the p53 gene allows a high 
intrinsic rate of genomic alterations such as translocations, chromosomal aberrations, 
aneuploidy, gene amplification, and mutations (Tainsky et al., 1995). This clearly demonstrates 
the importance of unaltered p53 function in regard to genomic stability and suggests that 
unaltered checkpoint function and induction of apoptosis are crucial in prevention of 
carcinogenesis.  
 
 However, the mutation of p53 often occurs very late in the stepwise process of 
tumorigenesis, e.g., colorectal cancer, and G2-M and S-phase checkpoints are only partially 
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affected in p53-deficient cells. It is therefore reasonable to expect other, p53-independent 
checkpoint controls to play a role in carcinogenesis.  
 
1.4.2 Ataxia telangiectasia 
 The study of a different human instability syndrome termed ataxia telangiectasia (AT) 
reinforced the role of checkpoints in genome maintenance and their impact on cancer, and it 
further pointed toward p53-independent checkpoints as important factors in DNA damage 
response. Homozygote patients with this rare, autosomal recessive genetic disorder suffer from 
cerebellar ataxia, oculocutaneous telangiectasia, immunodeficiency, premature aging, and an 
approximately 100-fold increased risk of cancer, particularly leukemias and lymphomas. 
Heterozygous carriers (approximately 1.4% of the caucasian US population) have a relative 
risk of cancer of 2.3 (men) to 3.1 (women), with an exceptionally high relative risk of breast 
cancer of 6.8 (Swift et al., 1987, 1994, 1997). It has been calculated that as many as 6.6% of 
all breast cancers in the US may occur in women heterozygous for AT (Athma et al., 1996). 
The defective gene in AT has recently been identified, and designated AT-Mutated or ATM 
(Savitsky et al., 1995). The ATM phenotype corresponds to some extent to the phenotype of 
NBS. Cells deriving from AT patients exhibit elevated sensitivity to IR and radiomimetic drugs 
and display chromosomal instability and abnormal genetic recombination (Gatti, 1991). 
Additionally, AT cells are defective in the induction of G1-S, S-phase, and G2 checkpoints in 
response to IR. The G1-S checkpoint deficiency is due, at least in part, to suboptimal induction 
of p53. In a signaling cascade activated by DNA damage, ATM acts upstream of p53 and there 
is compelling evidence that the ATM kinase directly phosphorylates p53 in vivo in response to 
DNA damage induced by IR (Canman et al., 1998). AT cells also fail to induce p53-
independent checkpoints indicating that the ATM lies far upstream in the cascade of detection 
and/or mediation of DNA damage signals. The above suggests that checkpoint defects are 
responsible for the AT related symptoms. Lately, ATM dysfunction has been associated with 
decreased DNA double strand break repair (Maser et al., 1997; Petrini et al., 1997) suggesting 
a role for ATM in induction of DNA repair. These studies suggest an integral role for ATM in 
cellular DNA damage responses.  
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 The cloning of the ATM gene unveiled an additional striking feature of checkpoint 
genes: ATM has significant sequence homology to genes in the yeast Schizosaccharomyces 
pombe (sprad3), Saccharomyces cerevisiae (scmec1 and sctel1) and Drosophila melanogaster 
(MEI-41), suggesting evolutionary conservation of checkpoint genes from yeast to humans 
(Savitsky, 1995; Zakian, 1995; Hoekstra, 1997). Because the homology extends to the PI-3 
kinase related region, they were all termed PI-3 kinase related kinases or PIKKs. So far all 
PIKKs are associated with functions in DNA damage response. For example, scMec1 and 
spRad3 both regulate checkpoint activation in response to DNA damage. Defects in the sprad3 
and scmec1 genes, like defects in ATM, also sensitize the organisms to radiation and 
radiomimetic drugs, additionally suggesting conservation of functional aspects of checkpoint 
pathways (Carr, 1997). 
 
1.5 Schizosaccharomyces pombe serves as a model system to 
study cell cycle control mechanisms 
 The similarities of genetic components in yeast and humans extend beyond these 
kinases. The fission yeast S. pombe has served for many years as a model system to study cell 
cycle control mechanisms and DNA damage-activated checkpoint responses. Large collections 
of yeast mutants that are sensitive to IR, UV light, and radiomimetic drugs have been identified 
in the last two decades (Elledge, 1996; Paulovich et al., 1997). With the advent of molecular 
biology and the genome sequencing projects, the genes responsible for the radiation sensitive 
phenotypes have been cloned. Many of the genes causing increased sensitivity are known as 
rad genes, for “radiosensitive” genes. Some of them are clearly involved in DNA repair 
mechanisms. Some gene products, however, regulate G2 and S-phase checkpoint delays along 
with G1 arrest, suggesting a critical role for checkpoint genes in cellular DNA damage 
responses (Kostrub et al., 1998; Longhese et al., 1998; Volkmer and Karnitz, 1999). 
 
 In S. pombe there are at least six genes (sprad1, sprad3, sprad9, sprad17, sprad26, 
and sphus1) that are crucial for induction of the G2 delays in response to DNA damage and 
replication blocking agents (al-Khodairy et al., 1994). Defects in one or more of these genes 
render the yeast more sensitive to genotoxic agents (Rowley et al., 1992; al-Khodairy and  
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Figure C. In a tentative model of G2 checkpoint activation an uncharacterized sensor recognizes DNA 
damage. The sensor(s) then interface with at least two kinases: the Rad3 kinase and the Chk1 kinase. 
The Rad3 kinase activates Chk1 by phosphorylation. This phosphorylation requires the five other 
checkpoint genes (rad1, rad9, rad17, rad26, and hus1), suggesting that their gene products operate 
upstream of Rad3. Chk1 then inactivates Cdc25, a cell cycle phosphatase in S. pombe, which prevents 
cell cycle transition through the G2-M boundary. 
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Carr, 1992; Enoch et al., 1992). Mutations in these genes do not affect cell cycle progression, 
suggesting that they regulate a common pathway of DNA damage response but are not 
essential under normal growth conditions (Collins et al., 1997). Based on genetic and 
biochemical evidence, a tentative pathway has been proposed for how fission yeast respond to 
DNA damage (Fig. C). Although still in their infancy, these studies suggest that an 
uncharacterized sensor recognizes DNA damage. Once activated, the sensor(s) then interfaces 
with a signaling pathway that is composed of at least two kinases: the Rad3 kinase and the 
Chk1 kinase. The Rad3 kinase lies upstream of and is required for Chk1 phosphorylation. This 
phosphorylation, in turn, activates Chk1 and requires the five other checkpoint genes (rad1, 
rad9, rad17, rad26, and hus1), suggesting that their gene products operate upstream of Rad3 
(Carr, 1996; Weinert, 1997). Once activated, Chk1 phosphorylates Cdc25, a cell cycle 
phosphatase required for the activation of the cyclin-dependent kinase Cdc2 in S. pombe. This 
finally prevents cell cycle transition through the G2-M boundary, thus linking DNA damage 
recognition to the cell cycle progression machinery (Furnari et al., 1997). Although genetic 
evidence in yeast and humans demonstrates the importance of the Rad3 and the ATM kinase, 
we have little understanding of how these kinases are activated by DNA damage or what 
regulates their activities. The other rad gene products, which are genetically required for Rad3 
function, may be key components that link the kinases Rad3 and Chk1 to DNA damage.  
 
1.5.1 Human homologs of the S. pombe checkpoint genes have been 
identified 
 Within the last five years, a panel of potential human homologs of the S. pombe 
checkpoint genes has been identified and molecularly cloned, further underscoring the 
similarities between yeast and humans (Table 1). This group of novel human genes includes 
homologs of sprad1 (hRAD1), sprad3 (ATM), sprad9 (hRAD9), sprad17 (hRAD17), sphus1 
(hHUS1), and spchk1 (hCHK1), all of which display a high degree of evolutionary 
conservation (Udell et al., 1998; Savitsky et al., 1995; Lieberman et al., 1996; Parker et al., 
1998; Kostrub et al., 1998; Sanchez et al., 1997). Some of these human homologs partially 
restore checkpoint function if expressed in the corresponding checkpoint mutant yeast cells, 
suggesting that the genes are functionally conserved (O’Connell et al., 2000). The similarity of 
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gene sequence and the partial conservation of function raises speculations about the function of 
human rad genes and their possible impact on the process of carcinogenesis. 
 
 
Table 1. Yeast homologs of human checkpoint genes 
 
Human   S. pombe   S. cerevisiae    Activity 
 
hRAD1   sprad1   scrad17    Exonuclease* 
 
ATM/ATR  sprad3   scmec1/sctel1   PIKK* 
 
hRAD9  sprad9   scddc1    * 
 
hRAD17  sprad17  scrad24   RFC-related* 
 
hRAD26  sprad26  -    * 
 
hHUS1  sphus1   -    * 
 
hCHK1  spchk1   -    PK 
 
hCDC25  spcdc25  -    Phosphatase 
 
hCDC2  spcdc2   -    CDK 
 
* known to be crucial for the DNA damage checkpoint in yeast 
 
 
 
 Assuming that, like in yeast, defects in a single checkpoint gene lead to abrogation of 
the G2 checkpoints, the effect in humans may be dramatic. DNA damage would no longer 
hinder the cells from progressing into mitosis creating a huge potential for development of 
mutated cells (Kaufmann et al., 1997). Inactivating mutations of rad genes may lead to 
increased rates of mutations and genomic instability as known for p53. Human checkpoint 
genes therefore have the potential to be tumor suppressors. Mapping of the human RAD9 gene 
(hRAD9) located it to a region for loss of heterozygosity in cervical cancer cell lines, 
suggesting that hRAD9 may be the causative tumor suppressor gene in this region (Lieberman 
et al., 1996). Likewise, the hRAD1 gene is located in a region that is subject to loss of 
heterozygosity in several human malignancies including lung cancer (Parker et al., 1998). Even 
if rad genes were not tumor suppressors, they may still cause an increased rate of mutation 
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required for initiation of tumor development. Because they have a crucial impact on 
maintenance of genomic stability, heterozygous defects within rad genes may be responsible 
for inherited predisposition to cancer, as are some of the known tumor suppressors.  
 
1.6 Clinical impact of checkpoint research 
 The aspect that renders investigation of alternative checkpoints clinically attractive is 
the potential of therapeutic exploitation of checkpoint research, for example for checkpoint-
based chemotherapy. More than 50% of all human malignant tumors contain defective p53. 
Loss of p53 function disrupts the G1-S checkpoint, which generally increases radiosensitivity 
of cells. However, p53-dependent pathways also lead to apoptosis, and lack of p53 reduces the 
ability to induce apoptosis in response DNA damage, which renders the cells less sensitive to 
genotoxic agents, e.g., chemotherapeutic drugs. In some tumor cell lines, this effect dominates 
the phenotype and, as a consequence, these tumor cell lines have reduced chemosensitivity and 
radiosensitivity (Lutzker and Levine, 1996). In order to increase therapeutic tumor-cell killing, 
it has been tested whether substances that abrogate the G2 checkpoints preferentially 
radiosensitize p53- tumor cells by disrupting G2 checkpoints, which potentially compensate for 
the absence of the genoprotective G1-S checkpoint (Powell et al., 1995). Selective G2-
checkpoint abrogators like UCN-01 (7-hydroxystaurosporine) increased killing of p53-
deficient tumor cells by γ-irradiation (Wang et al., 1996). UCN-01 is currently undergoing 
clinical trials for cancer treatment (Sausville et al., 2001). Interestingly, the G2-checkpoint 
abrogation is mediated by inhibition of Chk1, suggesting that other checkpoint proteins may be 
potential targets for cancer therapy as well (Busby et al., 2000; Graves et al., 2000). To devise 
a rational search for additional substances of use in checkpoint-based chemotherapy, 
investigation of the molecular mechanisms underlying checkpoint function is necessary. 
 
1.7 Aim of this study 
 In view of this potential importance of human rad genes in checkpoint control and 
possibly carcinogenesis, we have undertaken a cellular and molecular analysis of the novel 
human checkpoint proteins hRad9, hHus1, and hRad1 in K562 cells. Although these proteins 
have been identified, it is not yet clear how they regulate the responses of mammalian cells to 
DNA damage. Our aim was to determine whether and how hRad9, hHus1, and hRad1 are 
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involved in the basic molecular mechanisms of DNA damage response. Do they imitate 
molecular processes of yeast cells, suggesting conservation of checkpoint response from yeast 
to humans? To see whether the studies performed with human chronic myelogenous leukemia 
cells (K562) are representative for human skin cells, we performed identical experiments with 
human keratinocytes. As the skin is specifically exposed to UV irradiation, we analyzed, 
whether UV-induced DNA damage may differently affect hRad9-, hHus1-, and hRad1-
dependent molecular responses. We thus elucidated molecular mechanisms underlying the 
function of human checkpoint proteins hRad9, hHus1, and hRad1 in K562 cells and in human 
keratinocytes. This study facilitates future progress in our understanding of human checkpoint 
function and may permit advances in the development of new strategies in cancer therapy. 
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2 Materials and methods 
2.1 Chemicals and reagents 
2.1.1 List of chemicals 
α-HA monoclonal mAB   Babco, Berkeley, CA 
α-AU1 monoclonal mAB   Babco, Berkeley, CA 
α-FLAG monoclonal mAB   Kodak, New Haven, CT 
α-GFP rabbit antiserum   Molecular Probes, Eugene, OR 
Acrylamide     National Diagnostic, Atlanta, GA 
Acrylamide/bis               Sigma, St. Louis, MO 
Ammonium persulfate              Sigma, St. Louis, MO 
Ampicillin     Sigma, St. Louis, MO 
Aprotinin     Sigma, St. Louis, MO 
Bacto yeast extract    Difco, Detroit, MI 
Bacto tryptone    Difco, Detroit, MI 
Bacto agar     Difco, Detroit, MI 
β-Glycerophospate    Sigma, St. Louis, MO 
Bovine serum albumin (BSA)   Sigma, St. Louis, MO 
Bromophenol blue    IBI, New Haven, CT 
Calcium chloride (CaCl)   Aldrich, Milwaukee, WI 
Calf intestinal phosphatase (CIP)  Gibco BRL, Gaithersburg, MD 
Cesium chloride (CsCl)   Boehringer Mannheim, Indianapolis, IN 
EDTA      Sigma, St. Louis, MO 
Ethanol (100%)    Sigma, St. Louis, MO 
Ethidium bromide    Sigma, St. Louis, MO 
Expand high fidelity PCR system   Boehringer Mannheim, Indianapolis, IN 
Fetal calf serum (FCS)   Biofluids, Rockville, MD 
Glacial acetic acid (GAA)   EM Science, Gibbstown, NJ 
Glucose     Sigma, St. Louis, MO 
Glycerol     Sigma, St. Louis, MO 
Glycine     Sigma, St. Louis, MO 
Guanidine HCl               BRL Life Technologies, Gaithersburg, MD 
Hepes      Boehringer Mannheim, Indianapolis, IN 
Horseradish peroxidase (HRP)  Amersham, Arlington Heights, IL 
HRP-conjugated protein A   Amersham, Arlington Heights, IL 
Hydrochloric acid (HCl)   J.T. Baker, Phillipsburg, NJ 
Immobilon P membrane   Millipore, Bedford, MA 
Kanamycin     Sigma, St. Louis, MO 
KH2PO4     Sigma, St. Louis, MO 
K2HPO4     Sigma, St. Louis, MO 
LE agarose     FMC Bio Products, Rockland, MA 
L-glutamine     Sigma, St. Louis, MO 
Leupeptin     Sigma, St. Louis, MO 
Lysozyme     Boehringer Mannheim, Indianapolis, IN 
Magnesium chloride (MgCl2)   Sigma, St. Louis, MO 
2-β-Mercaptoethanol (2-ME)   Sigma, St. Louis, MO 
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Methanol (100%)    Sigma, St. Louis, MO 
Microcystin-LR    Sigma, St. Louis, MO 
Paraformaldehyde     Sigma, St. Louis, MO 
PCR-ready human testes cDNA library Clontech, San Diego, CA 
Pepstatin     Sigma, St. Louis, MO 
Potassium acetate (KAc)   Sigma, St. Louis, MO 
Potassium chloride (KCl)   Sigma, St. Louis, MO 
Propidium iodide (PI)    Sigma, St. Louis, MO 
Protein A sepharose beads   Sigma, St. Louis, MO 
Protein G sepharose beads   Sigma, St. Louis, MO 
Polaroid film type 53 (4 x 5”, b/w)  Polaroid Corporation, Cambridge, MA 
Polyoxyethylene sorbitan monolaureate 
 (TWEEN 20)    Sigma, St. Louis, MO 
Qiagen QIAquick gel extraction kit   Qiagen, Santa Clarita, CA 
Qiagen plasmid extraction kit   Qiagen, Santa Clarita, CA 
Rabbit-anti-mouse IgG   Pierce, Rockford, IL 
Rabbit-anti-mouse IgG, HRP-conjugated Pierce, Rockford, IL 
RPMI-1640 medium    Bio Whittaker, Walkersville, ML 
Sodium acetate (NaAc)   Sigma, St. Louis, MO 
Sodium azide (NaN3)    Sigma, St. Louis, MO 
Sodium chloride (NaCl)   Sigma, St. Louis, MO 
Sodium dodecyl Sulfate (SDS)  Sigma, St. Louis, MO 
Sodium fluoride (NaF)   Sigma, St. Louis, MO 
Sodium hydroxide (NaOH)   Sigma, St. Louis, MO 
Sodium orthovanadate (Na3VO4)  Fisher Scientific, Pittsburgh, PA 
Sodium phosphate (Na2HPO4) anhydrous Sigma, St. Louis, MO 
Sodium phosphate (7H2O)   Sigma, St. Louis, MO 
Super signal chemilumenescent substrate Pierce, Rockford, IL 
Tetramethyl-1,2-diaminoethane (TEMED) Sigma, St. Louis, MO 
TnT quick coupled transcription/ 
 translation system   Promega, Madison, WI 
Trichloroacetic acid    EM Science, Gibbstown, NJ 
Tris hydroxymethylaminoethane (TRIS) Sigma, St. Louis, MO 
TRIS HCl     Sigma, St. Louis, MO 
Triton-X 100     Sigma, St. Louis, MO 
Vectashield antifade mounting medium  Vector Laboratories, Burlingame, CA 
 
2.1.2 Enzymes 
2.1.2.1 Polymerase 
Expand high fidelity polymerase  Boehringer Mannheim, Indianapolis, IN 
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2.1.2.2 Ligase 
T4 DNA ligase    New England Biolabs, Beverly, MA 
 
2.1.2.3 Restriction enzymes 
Asc I      New England Biolabs, Beverly, MA 
EcoR I      New England Biolabs, Beverly, MA 
Xba I      New England Biolabs, Beverly, MA 
Xho I      New England Biolabs, Beverly, MA 
 
2.1.3 Epitope tags 
AU-1      Amino Acid Sequence: DTYRYI 
HA      Amino Acid Sequence: YPYDVPDYA 
FLAG      Amino Acid Sequence: DYKDDDDK 
GFP      Prasher et al., 1992 
 
2.1.4 Plasmids 
pcDNA3      Invitrogen, Carlsbad, CA 
pEF-BOS-∆RI     Mizushima et al., 1990 
pET24a+     Novagen, Madison, WI 
pGEX-KG     Guan and Dixon, 1991 
pGFP-N1     Clontech, San Diego, CA 
 
2.1.5 Genes 
hRAD1     Udell et al., 1998  
hRAD9     Lieberman et al., 1996 
hHUS1     Kostrub et al., 1998 
 
2.2 Instruments 
2.2.1 Centrifuges and rotors 
Ultracentrifuge L8-70 with  
NVT 65 rotor (rav=72.2 mm)  Beckman, Palo Alto, CA 
Microfuge R table top centrifuge with 
 F 241.5 rotor (rav=80 mm)  Beckman, Palo Alto, CA 
J2-21 centrifuge with  
JA-17 rotor (rav=123 mm)  Beckman, Palo Alto, CA 
 
2.2.2 Other instruments 
Bacteria cell incubator              Thelco, Pittsburgh, PA 
Cell counter coulter counter ZM  Coulter Pharmaceutical, Inc., Palo Alto, CA 
Confocal laser scanning  
microscope LSM510   Carl Zeiss Inc., Jena, Germany 
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137Cs γ-irradiator    J.L. Shepard, San Fernando, CA 
FS20 UVB lamp    Westinghouse, Pittsburgh, PA 
WG-295 long pass UVC filter             Schott Glass Technologies, Duryea, PA 
IL 443 UVB radiometer    International Light, Newburyport, MA 
SEE 240 photodetector   International Light, Newburyport, MA 
Electrophoresis unit Hoefer SE 600 series Hoefer Scientific Instruments, San Francisco, CA 
Electrophoresis unit Hoefer TE series 
 transphor    Hoefer Scientific Instruments, San Francisco, CA 
4 mm-electroporation cuvettes  BTX, San Diego, CA 
Electroporator BTX T 820   BTX, San Diego, CA 
Orbital shaker gene mate OS 350  Intermountain Scientific Corporation,  
      Kaysville, UT 
PCR thermocycler gene amp PCR 
system 9600    Perkin Elmer, Norwalk, CT 
Power supply power pac 1000  Bio-Rad Laboratories, Hercules, CA 
Polaroid MP 4+ gel camera   Polaroid Corporation, Cambridge, MA 
Power supply power pac 200   Bio-Rad Laboratories, Hercules, CA 
Safety stand BTX 630A    BTX, San Diego, CA 
Tissue culture incubator 4535   Forma Scientific, Marietta, OH 
 
2.3 Recipes 
2.3.1 Buffers and solutions 
30% Acrylamide stock for SDS-PAGE 
300.0 g Acrylamide       (29.2%) 
8.2 g Acrylamide/bis       (0.4%) 
adjust the volume to 1027 ml with deionized water 
- filter solution through a 0.45 µm filter to remove particles 
 
Agarose gel loading buffer (100 ml of 5X stock) 
- to 30 ml of deionized water, add: 
50 ml glycerol        (50%) 
10 ml of 50X TAE       (5X) 
- add 500 µg SDS       (0.5%) 
- add 250 µg bromophenol blue     (0.25%) 
- adjust the volume to 100 ml with deionized water 
 
GTE buffer (20 ml)  
- to 10 ml of deionized water, add: 
180 mg glucose        (50 mM) 
0.4 ml of 2 M TRIS HCL, pH=8.0      (25 mM) 
0.4 ml EDTA         (10 mM) 
- adjust the volume to 20 ml with deionized water 
 
EDTA (100 ml of 500 mM stock) 
- to 50 ml deionized water, add: 
18.6 g EDTA         (500 mM) 
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- adjust to pH 8.0 with concentrated HCl 
- adjust the volume to 100 ml with deionized water 
 
KAc solution (30 ml) 
- to 18 ml of 5 M KAc, add:      (3 M) 
3.5 ml glacial acetic acid       (11.7%) 
- adjust the volume to 30 ml with deionized water 
 
Resolving gel buffer (1000 ml) 
- to 750 ml of deionized water, add: 
181.7 g TRIS         (1.5 M) 
4 g SDS         (0.4%) 
- adjust to pH 8.8 with concentrated HCl 
- adjust the volume to 1000 ml with deionized water 
 
Lysis buffer (500 ml) 
- to 250 ml of deionized water, add: 
25 ml HEPES         (50 mM) 
5 g Triton X 100        (1%) 
0.21 g NaF         (10 mM) 
6.7 g Na4P207         (30 mM) 
15 ml of 5 M NaCl        (150 mM) 
1 ml of 500 mM EDTA stock      (1 mM) 
- adjust the volume to 500 ml with deionized water 
- prior to use add freshly:  
β-glycerophosphate to 10 mM     (10 mM) 
Na3VO4 to 1 mM       (1 mM) 
pepstatin A to 20 µg/ml      (20 µg/ml) 
aprotinin to 10 µg/ml       (10 µg/ml) 
leupeptin to 20 µg/ml       (20 µg/ml) 
microcystin-LR to 40 µM      (40 µM) 
 
Lysozyme solution  
- to 2 ml of GTE buffer, add: 
100 mg lysozyme        (5%) 
 
NaOH/SDS buffer (34 ml) 
- to 20 ml of deionized water, add: 
680 µl of 10 N NaOH       (0.2 M) 
3.4 ml of 10% SDS        (1%) 
- adjust the volume to 34 ml with deionized water 
 
PBS washing buffer (1000 ml of 10X stock) 
- to 750 ml of deionized water, add: 
2.0 g KCl        (26.9 mM) 
2.0 g KH2PO4         (14.7 mM) 
80 g NaCl         (1.37 M) 
21.6 g Na2HPO4x7H2O      (80.6 mM) 
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- adjust the volume to 1000 ml with deionized water 
SDS sample buffer (100 ml of 4X stock) 
- to 10 ml of deionized water, add: 
3.0 g TRIS         (250 mM) 
40 ml glycerol        (40%) 
9.2 g SDS         (9.2%) 
400 µg bromophenol blue       (0.4%) 
- adjust the volume to 100 ml with deionized water 
- prior to use add 2-ME to 10 %     (10%) 
 
SDS running buffer (2000 ml of 10X stock) 
- to 1500 ml of deionized water, add: 
60.6 g TRIS         (250 mM) 
288.0 g glycine        (14.4%) 
20.0 g SDS         (1%) 
- adjust the volume to 2000 ml with deionized water 
 
SDS transfer buffer (2000 ml of 10X stock) 
- to 1500 ml of deionized water, add: 
60.6 g TRIS         (250 mM) 
288.0 g Glycine        (14.4%) 
- adjust the volume to 2000 ml with deionized water 
 
TAE (1000 ml of 50X stock) 
- to 500 ml deionized water, add: 
242 g TRIS         (2 M) 
51.1 ml acetic acid        (5.11%) 
18.6 g EDTA         (500 mM) 
- adjust the volume to 1000 ml with deionized water 
 
TBS (4000 ml of 10X stock) 
- to 3000 ml deionized water, add: 
242 g TRIS        (500 mM) 
350.65 g NaCl        (1.5 M) 
- adjust the volume to 4000 ml with deionized water 
- adjust to pH 7.4 if necessary 
 
TE (509 ml) 
- to 500 ml deionized water, add: 
1 ml 0.5 M EDTA of pH=8.0      (1 mM) 
8 ml 1 M TRIS HCL at pH=7.4      (20 mM) 
- adjust to pH 7.5 if necessary 
 
Stacking gel buffer (500 ml) 
- to 350 ml of deionized water, add: 
30.3 g TRIS         (0.5 M) 
2.0 g SDS         (0,4%) 
- adjust to pH 6.8 with concentrated HCl 
  
 
21
- adjust the volume to 500 ml with deionized water 
 
2.3.2 Media and gels 
1%-Agarose gel (100 ml) 
to 100 ml of deionized water, add: 
1 g agarose (1%) 
- heat to 100°C 
- adjust the volume to 100 ml with deionized water 
- add 20 µl/100 ml ethidium bromide 
- cast gel in gel tray 
- allow gel to polymerize 
 
2%-Agarose gel (100 ml) 
to 100 ml of deionized water, add: 
2 g agarose (1%) 
- heat to 100°C 
- adjust the volume to 100 ml with deionized water 
- add 20 µl/100 ml ethidium bromide 
- cast gel in gel tray 
- allow gel to polymerise 
 
LB-ampicillin liquid medium (1000 ml) 
- prepare LB liquid medium as described 
- place stir bar into flask before autoclaving 
- sterilize by autoclaving (20 min, 15 lb/sq) 
- allow solution to cool to 60°C 
- add 50 µg/ml ampicillin  
- stir for 5 min 
 
LB-ampicillin plates (approx. 1000 ml or 20-25 plates) 
- prepare LB plates as described 
- place stir bar into flask before autoclaving 
- sterilize by autoclaving (20 min, 15 lb/sq) 
- allow solution to cool to 60°C 
- add 50 µg/ml ampicillin  
- stir for 5 min 
- cast into 100 mm Falcon culture dishes (20-25 ml each) 
 
LB plates (approx. 1000 ml or 20-25 plates) 
- to 900 ml of deionized water, add: 
10 g Bacto tryptone 
5 g Bacto yeast extract 
10 g NaCl 
- adjust the volume to 1000 ml with deionized water 
- add 20 g Bacto agar and place stir bar into flask 
- sterilize by autoclaving (20 min, 15 lb/sq) 
- allow solution to cool to 60°C 
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- cast into 100 mm Falcon culture dishes (20-25 ml each) 
 
Luria broth (LB) liquid medium (1000 ml) 
- to 950 ml of deionized water, add: 
10 g Bacto tryptone 
5 g Bacto yeast extract 
10 g NaCl 
- adjust to pH 7.0 with 5 N NaOH 
- adjust the volume to 1000 ml with deionized water 
- sterilize by autoclaving (20 min, 15 lb/sq) 
 
10% SDS-PAGE gel 
- to 13 ml of deionized water, add: 
8 ml resolving gel buffer 
11 ml of 30% acrylamide 
50 µl APS 
25 µl TEMED 
- cast gel between glass plates 
- when gel has polymerized, prepare: 
stacking gel 
- to 3 ml of deionized water, add: 
1.3 ml stacking gel buffer 
0.8 ml of 30% acrylamide 
15 µl APS 
5 µl TEMED 
- cast stacking gel on top of polymerised 10% SDS-PAGE gel 
 
Terrific broth (TB) liquid medium (1000 ml) 
- to 900 ml of deionized water, add: 
12 g Bacto tryptone 
24 g Bacto yeast extract 
4 ml glycerol 
- sterilize by autoclaving (20 min, 15 lb/sq) 
- allow solution to cool to 60°C 
- adjust the volume to 900 ml with sterile deionized water 
- add 100 ml of a sterile solution of 0.17 M KH2PO4 and 0.72 m K2HPO4 
  
 
23
2.4 Experimental procedures 
2.4.1 Cell culture, γ-irradiation, and UV irradiation 
 Cells from the human chronic myelogenous leukemia cell-line K562 (Lozzio and 
Lozzio, 1977) were cultured in RPMI-1640 medium supplemented with 10% fetal calf serum 
(FCS) and 2 mM L-glutamine under 5.5% CO2 at 37°C in a tissue culture incubator. Cultures 
were maintained in exponential growth phase (0.5x106 cells/ml). Cell counts were carried out 
using an automated cell counter. Keratinocytes were isolated from human foreskin specimens. 
Primary cultures were maintained in a replicative state with complete MCDB 153 medium. 
Secondary cultures were plated (1-10x103 cells per cm2) and medium was supplemented with 
0.2% bovine pituitary extract (BPE), 0.1 mM calcium, 10 ng/ml EGF, 5 µg/ml insulin, 5x10-7 
M hydrocortisone 1x10-4 M ethanolamine, and 1x10-4 M phosphoethanolamine. Keratinocytes 
were then grown to confluence in standard medium for 48 hrs. Cells were γ-irradiated as 
indicated at a dose rate of 11.4 Gy/min using a 137Cs γ-irradiator. UV irradiation was 
performed using a FS20 UVB lamp in combination with a WG-295 long pass UVC filter. 
Quantification of the emitted doses were regularly performed using the IL 443 UVB 
radiometer combined with a SEE 240 photodetector.  
 
2.4.2 Cloning and epitope-tagging 
2.4.2.1 pcDNA3-AU1-hRAD9 and pcDNA3-GFP-hRAD9 
 The hRad9 cDNA was amplified by PCR (”touchdown-PCR”) from a PCR-ready 
human testes cDNA library using the oligonucleotide primer pair 5’-ATG AAG TGC CTG 
GTC ACG GGC GGC AAC GTG AAG-3’ and 5’-TCA GCC TTC ACC CTC ACT GTC 
TTC CGC CAG CAC-3’. The PCR products were then re-amplified using the oligonucleotide 
5’ primer 5’-CAG CTG CAG AGG CGC GCC AAG TGC CTG GTC ACG GGC GGC-3’ 
that removed the initiating Met codon (5’-ATG-3’) and appended an Asc I restriction enzyme 
site (5’-GGC GCG CC-3’) 5’ of the second codon in hRad9. The Asc I site was added to 
provide an in-frame fusion with either tandem AU1 epitope tags or green fluorescent protein 
(GFP). The 3’ primer 5’-CGC CTC GAG TCT AGA TCA GCC TTC ACC CTC ACT GTC-
3’ added an Xba I site (5’-TCT AGA-3’) immediately after hRad9’s stop codon (5’-TGA-3’). 
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The resulting PCR fragment was digested with Asc I and Xba I and cloned into Asc I- and Xba 
I-digested pcDNA3 that had been pre-engineered to contain a 5’ GFP or AU1 epitope tag. 
 
2.4.2.2 pcDNA3-FLAG2-hRAD1 
 To prepare the hRad1 mammalian expression vector, its cDNA was PCR-amplified 
using the primers 5’-ATG CCC CTT CTG ACC CAA CAG ATC-3’ and 5’-TCA AGA CTC 
AGA TTC AGG AAC TTC-3’. The amplified fragment was then re-amplified with the 5’ 
primer 5’-GCA GGT ACC GAA TTC GCC GCC ATG GAC TAC AAA GAC GAT GAC 
GAC AAG GGA GAT TAC AAG GAT GAC GAT GAC AAA GGA GCC GGC GCT GGC 
GCG CCT CCC CTT CTG ACC-3’ that incorporated an EcoR I site (5’-GAA TTC-3’), and a 
tandem FLAG epitope tag (5’-ATG GAC TAC AAA GAC GAT GAC GAC AAG GGA GAT 
TAC AAG GAT GAC GAT GAC AAA-3’) fused in-frame with hRad1. Immediately upstream 
of the first codon of the tandem FLAG epitope tag, a Kozak consensus sequence (5’-GCC 
GCC-3’) was incorporated. The 3’ primer 5’-CTG TCT AGA CTC GAG TCA AGC CTC 
AGA TTC AGG AAC TTC-3’ added an Xho I site (5’- CTC GAG-3’) after hRad1’s stop 
codon. The resulting PCR fragment was digested with EcoR I and Xho I and cloned into EcoR 
I- and Xho I-digested pcDNA3 to yield pcDNA3-FLAG2-hRad1. 
 
2.4.2.3 pEF-BOS-∆RI-HA2-hHUS1 
 The hHUS1 mammalian expression vector was prepared by amplifying hHUS1 using 
the primers 5’-ATG AAG TTT CGG GCC AAG ATC CTG-3’ and 5’-GGA CAG TGC AGG 
GAT GAA ATA CTG-3’. The resulting PCR fragment was then re-amplified with the 5’ 
primer 5’-CAG GGT ACC GAA TTC GCC GCC ATG AAG TTT CGG GCC AAG ATC 
GTG-3’ that added an EcoR I site and Kozak consensus sequence immediately upstream of the 
initiating Met codon. The 3’ primer 5’-CAG CTC GAG TGG CGC GCC GGA CAG TGC 
AGG GAT GAA ATA CTG-3’ removed the native stop codon, and appended an Asc I site 
(5’-GGC GCG CC-3’). The Asc I site provided an in-frame fusion with a tandem HA epitope 
tag that was pre-engineered into pEF-BOS-∆RI. The PCR-derived DNA fragment was 
digested with EcoR I and Asc I and cloned into the EcoR I and Asc I sites of the HA-modified 
pEF-BOS-∆RI. 
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2.4.3 DNA quantification 
To determine DNA concentration, solution was diluted 1:25 in TE, and optical density (OD 
reading) was determined photometrically at wavelength λ=260 nm. 
 
2.4.4 Amplification of DNA by polymerase chain reaction 
2.4.4.1 Standard procedure 
 All polymerase chain reaction (PCR) amplifications were performed with the Expand 
high fidelity PCR system using the buffer provided by the company. A standardized setup was 
applied for all PCR reactions: the template mixture was prepared by mixing 2 µl of the 5’-
primer and 3’-primer, both at 10 µM, 5 µl of DNA template (100 ng/ml) and 5 µl of dNTP (2 
mM each) to 34 µl of sterile deionized water and placed on ice. The Master Mix (10 µl of 10X 
PCR buffer, 39 µl of sterile distilled water and 1 µl of Expand high fidelity polymerase) was 
prepared freshly. The template mixture was now placed on the heating block of the PCR 
thermocycler, which was preset to 94°C. The Master Mix was mixed to template mixture to a 
total reaction volume of 100 µl, and the thermocycler was started. For all common PCR 
amplifications, 30 cycles were performed with the denaturing temperature held at 94°C for 10 
sec, the annealing temperature at 62°C for 30 sec and the synthesizing temperature at 72°C for 
4 min. 
 
2.4.4.2 “Touchdown-PCR” 
 Only amplifications of DNA from the cDNA library were performed using a 
”touchdown-PCR” protocol. Here, during the first 5 cycles, the denaturing temperature was 
held at 94°C for 10 sec and then cooled to 72°C, where the temperature was held for 3 min. 
During the following 5 cycles the temperature was held at 94°C for 10 sec and then ramped 
down to 70°C where it remained for 3 min. For the final 25 cycles the PCR machine denatured 
at 94°C for 10 sec, then ramped down to the annealing temperature of 64°C, which it held for 
30 sec and then ramped up to the synthesis temperature of 70°C for 3 min. 
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2.4.5 Agarose gel electrophoresis 
 Agarose gel electrophoresis was used to either check the outcome of PCR 
amplifications, to analyze newly generated plasmids, or to gel-purify restriction enzyme 
digestions. According to the size of DNA fragments, the agarose gel was cast at 1% [for 
fragments larger than 500 base pairs (bp)], or at 2% (for fragments smaller than 500 bp). DNA 
products were mixed with 5X agarose gel loading buffer and separated at 100 V for 60 min. A 
Polaroid MP 4+ Gel Camera was used to take a Polaroid picture during UV transillumination 
of agarose gels to document and analyze the results of the electrophoresis. For agarose gel 
purification of DNA, appropriate bands were quickly cut out of the gel and purified using the 
Qiagen QIAquick gel extraction kit. 
 
2.4.6 Restriction enzyme digestions 
 Restriction enzyme digestions were performed using the appropriate enzymes and the 
provided buffer purchased from New England Biolabs. For double-digestions of PCR products 
with two different restriction sites on the 5’ and the 3’-end, respectively, 30 µl of PCR 
products were mixed with 5 µl of 10X reaction buffer, 11 µl of distilled water and 2 µl of each 
enzyme (20 units) to a total reaction volume of 50 µl. The reaction was incubated for 2 hrs at 
37°C, and the reaction products were agarose gel purified. For double digestions of expression 
vectors, digestion was performed as described above, except the amount of DNA was limited 
to 5 µg, and the reaction mix was adjusted with distilled water.  
 
2.4.7 Ligations 
 Ligations were performed to clone a PCR-amplified gene into a mammalian expression 
vector using T4 DNA ligase and the provided buffer purchased from New England Biolabs. 2 
µl of 10X-reaction buffer were mixed with 1 µl of gel-purified expression vector 
(approximately 5 µg/ml), 2 µl of gel-purified PCR products (approximately 10 µg/µl), 16 µl of 
distilled water and 1 µl of T4 DNA ligase (20000 U/ml) to a total reaction volume of 20 µl. 
The reaction was incubated for 12 hrs at 16°C. The resulting ”ligation-mix” was then used to 
transform competent bacteria as described below. 
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2.4.8 Transformations 
 To amplify the amount of plasmid DNA the competent Escherichia coli strain DH5α 
was transformed using a heat-shock protocol. 500 µl of DH5α were incubated on ice with 1-2 
µl of ”ligation-mix” for 30 min. Then, the cells were heat-shocked in a 42°C waterbath for 40 
sec and cultured in 600 µl of LB for 1 hr. All bacterial cultures were grown with shaking (300 
rpm) at 37°C in an orbital shaker. Because the plasmids confer ampicillin resistance, bacterial 
cells were plated on LB-amp plates to select for transformed cells and incubated overnight at 
37°C. 
 
2.4.9 DNA mini-preparation 
 Selected transformants were picked from overnight culture, and grown in an expansion 
culture of 2 ml LB for 5-8 hrs at 300 rpm in the orbital shaker at 37°C. At this step 500 µl of 
cell culture was saved as a glycerol stock (add 500 µl glycerol to 500 µl of bacteria cell 
suspension and freeze to -70°C) for use in CsCl preparations (see below). Plasmids were 
extracted using the Qiagen plasmid extraction kit following manufacturer’s instructions. 
Extracted plasmid clones were then digested with restriction enzymes and analyzed by agarose 
gel electrophoresis (1% gel). A polaroid picture was taken to analyze the size of the fragments. 
All plasmids consisting of the right size fragments of vector and insert were selected for 
automated sequencing and those bearing no mutations were selected for cesium chloride 
preparation. 
 
2.4.10 Cesium chloride DNA preparation 
 To obtain sufficient amounts of plasmid to carry out transient cell transfections, cesium 
chloride preparations were performed for each expression vector. Plasmid-containing 
transformants from glycerol stocks (see DNA mini-preparation) were streaked to single 
colonies on LB dishes containing the appropriate antibiotic (100 µg/ml ampicillin or 30 µg/ml 
kanamycin) required to select for plasmid and incubated at 37°C until colonies were of 1-2 mm 
in diameter. A single colony was picked, and transferred to a sterile 50 ml Falcon tube 
containing 10 ml of liquid LB-antibiotic. Bacteria-cell suspension was incubated for 8 hrs in the 
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orbital shaker. All incubations were carried out under vigorous shaking (300 rpm) and at 37°C. 
Subsequently, 1.25 ml of start-up culture were transferred to a sterile 1000 ml Erlenmeyer 
flask. 125 ml of antibiotic containing Terrific Broth (TB-antibiotic) were added, and the 
suspension was incubated for 12-14 hrs. Then, cells were transferred to 250 ml Nalgene 
centrifuge tube and centrifuged at 3700 rpm for 20 min. The cell pellet was re-suspended in 16 
ml of freshly prepared GTE buffer and added to a sterile 250 ml beaker. After 10 min of 
incubation with 2 ml of lysozyme solution at 37°C, cells were lysed for 5 min by addition of 32 
ml of NaOH/SDS buffer. Thereafter, to precipitate the SDS protein complexes, 26 ml of KAc 
solution were added to cell lysates, and the solution was shaken, and incubated on ice for 15 
min. To separate DNA from cell debris, the solution was centrifuged in a Beckman J2-21 
centrifuge equipped with a JA-17 rotor at 17000 rpm (40000xg) for 20 min at 4°C. The 
supernatant was filtered through a fine mesh and precipitated by addition of 2 volumes of 
100% ethanol. To collect the precipitated DNA, solution was centrifuged for 20 min at 3000 
rpm at 4°C, the supernatant was discarded carefully, and the DNA pellet was air-dried to 
remove the residual ethanol. The dry pellet was dissolved in 16 ml TE. To separate plasmid 
DNA from chromosomal DNA, a cesium-chloride (CsCl) gradient (1 g/ml) was induced by 
addition of 20 g of CsCl to dissolved DNA. Additionally, 0.45 ml of ethidium bromide (10 
mg/ml) and 0.45 ml of sarcosyl were added. The solution was then filled into two 11.2 ml 
OptiSeal ultracentrifuge tubes and centrifuged at 60000 rpm (∼371000xg) at 25°C for 8 hrs 
using a Beckman L8-70 Ultra Centrifuge equipped with a NVT 65 rotor. The plasmid-
containing band (lower pink band) was removed using a sterile syringe and needle. The volume 
(V) was measured, and TE was added to a total of 17.2 ml. To create the second CsCl 
gradient, [19.8 g - (V) g] CsCl and 0.4 ml ethidium bromide were added. Gradients were 
centrifuged for 8 hrs (60000 K, 25°C). The plasmid-containing bands were aspirated with a 
sterile syringe and needle. To remove the ethidium bromide, the volume was adjusted to 5 ml 
with TE. 15 ml of 95% ethanol were added to precipitate DNA. Centrifugation in the Beckman 
J2-21 centrifuge equipped with a JA-17 rotor at 7000 rpm (10000xg) provided a DNA pellet 
that was again dissolved in 5 ml TE. This step was repeated until DNA was no longer pink, 
which indicated that it was clear of ethidium bromide. The final precipitate was dissolved in 5 
ml TE, and the concentration of DNA was determined photometrically at wavelength λ=260 
nm. 
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2.4.11 Transient transfections 
 To transiently express a gene of interest in K562 cells, the expression vector was 
introduced into the cell by electroporation. All electroporations (transfections) used 40 µg of 
plasmid DNA, which included empty vector added to this amount, if necessary. For 
precipitation, DNA was aliquotted into an Eppendorf tube, and TE buffer was added to 300 µl. 
After addition of 30 µl of 3 M sodium acetate and 600 µl of 95% ethanol, the tube was shaken 
thoroughly and subsequently centrifuged for 5 min at 20000xg. The supernatant was carefully 
aspirated, and an additional 1 ml of 95% ethanol was added to wash the DNA pellet. After 
centrifugation for 30 sec at 20000xg, all traces of ethanol were vacuum-aspirated using a 
sterile needle under the tissue culture hood. The DNA precipitate was then dissolved for 20 
min in 50 µl RPMI 1640 medium without FCS and L-glutamine with occasional vortexing. For 
each transfection, 1x107 K562 cells in exponential growth phase were pelleted by centrifuging 
(800xg), and all traces of medium were aspirated. The cells were re-suspended in 350 µl 
RPMI-1640 medium (with 10% FCS and L-glutamine) and incubated with dissolved DNA (50 
µl) in a total volume of 400 µl. After 5 min, the cell-DNA mixture was transferred to a 4 mm 
BTX electroporation cuvette. A BTX T 820 electroporator was used to deliver a 344-volt, 10-
msec pulse. Electroporated cells were plated on 100 mm Falcon culture dishes in FCS/L-
glutamine-containing RPMI-1640 medium and cultured for 16-24 hrs before use in 
experiments. The construction, operation and efficiency of the electroporation apparatus have 
been described (Fakhrai et al., 1996; Takahashi et al., 1991) 
 
2.4.12 Co-immunoprecipitation experiments 
 Exponentially growing K562 cells were either transfected as indicated above or used 
directly for immunoprecipitation studies. Cells were centrifuged for 5 min (800xg), washed in 
PBS, and lysed in lysis buffer. The cell lysates were then immunoprecipitated with the indicated 
mouse monoclonal antibodies and protein G-Sepharose or rabbit antisera and protein A-
Sepharose for 1 hr at 4°C. The immunoprecipitates were washed three times with lysis buffer, 
heated to 100°C for 5 min in 1X-SDS-PAGE sample buffer, and fractionated in 10% gels by 
sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE). A Hoefer SE 600 
series Electrophoresis Unit in combination with a Power Pac 1000 power supply was used to 
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run the gels. The gels were transferred to Immobilon P membranes. For transfer runs, a Hoefer 
TE series Transphor Electrophoresis Unit in combination with a Power Pac 200 was used. 
Subsequently, the membranes were blocked in 5% bovine serum albumin (BSA) in TBS 
containing 0.2% Tween 20, and immunoblotted with the indicated antibodies or antisera in 
TBS containing 0.2% Tween 20 and 5% BSA. hRad9, hHus1, and hRad1 rabbit antisera were 
diluted 1:500 while the monoclonal mouse antibodies (mAB) were diluted 1:5,000. For 
immunoblots with the mAB, the membranes were washed and then incubated with rabbit anti-
mouse IgG conjugated to horseradish peroxidase (1:5,000 dilution) or rabbit anti-mouse IgG 
in TBS containing 0.2% Tween 20 (1:5,000 dilution), followed by incubation with horseradish 
peroxidase-conjugated protein A (1:10,000 dilution). For immunoblots with rabbit antisera, 
after incubation in the primary rabbit antibody solutions, the blots were washed and then 
incubated with horseradish peroxidase-conjugated protein A (1:10,000 dilution). All 
membranes were developed with SuperSignal chemiluminescent substrate. 
 
2.4.13 Sequential blotting 
 For membranes that were sequentially blotted with different antisera, the membranes 
were stripped of bound antibodies with two 30-minute washes of 8 M guanidine hydrochloride, 
prior to blocking and immunoblotting. 
 
2.4.14 Mobility shift experiments 
 Exponentially growing K562 cells (1x107 per assay point) were treated with the 
indicated stimuli and cultured as described. The cells were then centrifuged (800xg, 5 min), 
washed with PBS, and lysed in lysis buffer. The lysates were clarified by centrifugation for 5 
min at 21,000xg in a table top centrifuge at 4°C and rotated with 5 µl anti-hRad9 antiserum on 
protein A-Sepharose for 1 hr. The immunoprecipitates were washed three times with lysis 
buffer, heated at 100°C for 5 min in 1X SDS-PAGE sample buffer, and fractionated by SDS-
PAGE (10% gel). The gels were transferred to an Immobilon-P membrane, and the membranes 
were immunoblotted with a 1:500 dilution of anti-hRad9 antiserum in TBS containing 0.2% 
Tween 20. The antigen-antibody complexes were detected with a 1:10,000 dilution of 
horseradish peroxidase-conjugated protein A.  
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2.4.15 Phosphatase experiments 
 Exponentially growing K562 cells (1x107 per sample) were treated with 0 or 50 Gy IR 
and cultured for 5 hrs at 37°C. The cells were then lysed, and hRad9 was immunoprecipitated 
as described above. The immunoprecipitates were washed three times with lysis buffer and 
three times with 50 mM TRIS, pH 8.5, 0.1 mM EDTA. Samples that were not treated with 
phosphatase were then mixed with SDS-PAGE sample buffer. Samples treated with 
phosphatase were incubated with 0.25 units of calf intestinal phosphatase for 30 min at 30°C, 
with or without 50 mM β-glycerophosphate, following manufacturer’s directions (Gibco BRL, 
Gaithersburg, MD). After phosphatase treatment, the immunoprecipitates were washed once 
with lysis buffer, mixed with SDS-PAGE sample buffer, and fractionated by SDS-PAGE (10% 
gel). 
 
2.4.16 In vitro translations 
 These were performed with the TnT Quick Coupled Transcription/Translation System 
using pcDNA3-FLAG2-hRAD1 and pcDNA3-hHUS1-HA2 as templates for the reactions. A 
portion (10 µl) of each translation reaction was prepared for SDS-PAGE. The remainder of 
each was divided into two parts. Each part (20 µl) was diluted into 1 ml of lysis buffer and was 
immunoprecipitated with either anti-FLAG mAb or anti-HA mAb and protein G-Sepharose, 
and fractionated by SDS-PAGE (10% gel). 
 
2.4.17 Antibodies 
 Bacterial expression vectors for hexahistidine-tagged hRad1 and hHus1 were generated 
by cloning PCR-amplified DNA fragments into pET24a+. Histidine-tagged proteins were 
induced and purified according to manufacturer’s instructions. PCR-derived DNA fragments 
for hRad9 were cloned into pGEX-KG to generate an in-frame fusion with glutathione S-
transferase (GST). Bacterially produced GST-hRad9 was purified by affinity chromatography 
on glutathione agarose (GSH). The purified proteins were used to immunize rabbits to 
generate antisera against hRad9, hHus1, and hRad1. The anti-GFP rabbit antiserum was 
obtained from Molecular Probes (Eugene, OR). The anti-HA and anti-AU1 monoclonal 
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antibodies were purchased from Babco (Berkeley, CA), and the anti-FLAG mAb was from 
Kodak (New Haven, CT). 
 
2.4.18 Fluorescent microscopy 
 To explore a proteins localization within the cell, the protein was epitope-tagged with 
enhanced green fluorescent protein (GFP). GFP is a monomeric protein of 27 kDa (238 amino 
acids). It autocatalytically forms a fluorescent pigment that emits green light in response to 
excitation (maximally at 488 nm) in the absence of any co-factors. GFP may therefore be used 
as a fluorescent tag to monitor protein localization. (Chalfie et al., 1994). Exponentially 
growing K562 cells (5x106 per sample) were transfected with 5 µg GFP-tagged hRad9, 5 µg 
GFP-N1 alone and empty vector as described. Approximately 15000 cells were spun down on 
a coverslip using a cytospin centrifuge. Cells were fixed on coverslips with 4% 
paraformaldehyde in PBS for 3 min, and subsequently, nuclei were counter-stained for 3 min 
with 10 µg/ml propidium iodide in PBS (red fluorescence in response to excitation). Coverslips 
were air-dried and mounted on microscope slides with Vectashield Antifade Mounting 
Medium. Coverslips were sealed with clear nail polish. Fluorescent microscopy was performed 
at a wavelength of 488 nm using the Confocal Laser Scanning Microscope LSM510. Images 
were created with the LSM510 software for windows NT and saved as TIFF files. 
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3 Results 
3.1 Human checkpoint proteins hRad9, hHus1, and hRad1 
associate in a complex 
 Comparisons of the predicted protein sequences of the human proteins analyzed in this 
study (hRad9, hHus1, and hRad1) to their putative homologs in the fission yeast S. pombe 
reveal homologies widely extending over large portions of each protein. The human proteins 
are 25-30% identical and 52-57% similar to their respective homologs at the amino acid level 
(Udell et al., 1998; Savitsky et al., 1995; Lieberman et al., 1996; Parker et al., 1998; Kostrub 
et al., 1998; Sanchez et al., 1997; Freire et al., 1998). In wild-type fission yeast (S. pombe), the 
checkpoint proteins spRad1 and spHus1 interact genetically as well as physically, 
demonstrating that checkpoint proteins form biochemical complexes. This interaction does not 
occur in yeast with mutant spRad9, suggesting that spRad9 is required for hHus1-hRad1 
interaction. One interpretation of this result is that spRad9 may physically link spRad1 to 
spHus1, although this hypothesis has not been validated experimentally (Kostrub et al., 1998).  
 
 To address whether structural organization of the checkpoint protein complexes are 
conserved from yeast to humans, we examined the ability of the human homologs of spRad9, 
spHus1, and spRad1 to form biochemical complexes similar to those reported in yeast. Using 
polyclonal rabbit antibodies of hRad9, hHus1, and hRad1 we immunoprecipitated each protein 
from detergent cell lysates of exponentially growing K562 cells. The precipitates were then 
separated by SDS-PAGE, transferred to a membrane, and sequentially immunoblotted with 
antibodies that recognize the potential interaction partners. 
 
 Human K562 cell lysates that were immunoprecipitated with anti-hHus1 antiserum 
(Fig. 1A, left panel) contained a protein band of 34 kilodalton (kDa), which was similar in size 
to hHus1’s predicted molecular weight of 32 kDa. The hHus1 immunoprecipitates also 
contained a 33-kDa band, which reacted with the anti-hRad1 antiserum (Fig. 1B, left panel). 
This band co-migrated with immunoprecipitated hRad1 and corresponded in size to hRad1’s 
predicted mass of 31 kDa, suggesting that hRad1 physically binds to hHus1 in vivo. 
Immunoblotting of the hHus1 immunoprecipitates with anti-hRad9 antiserum revealed a 70-
kDa band (Fig. 1C, left panel) that co-migrated with a band in the anti-hRad9 precipitates (Fig. 
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1C, right panel). This was surprising, as hRad9 has a predicted molecular mass of 45 kDa, 
which is much smaller than the 70-kDa band observed. As will be shown, the hRad9 protein 
undergoes extensive post-translational modification (Fig. 2, 3), which likely accounts for the 
discrepancy between its apparent and predicted molecular masses. We therefore conclude that 
hRad9, as well as hRad1, physically binds to hHus1 in vivo.  
 
Figure 1. hRad9, hHus1, and hRad1 associate in a stable complex. (A) Lysates prepared from 
exponentially growing K562 cell (1x107 per sample) lysates were immunoprecipitated with either 
preimmune (PI) antisera or with anti-hRad9, anti-hRad1, or anti-hHus1 rabbit antisera. After extensive 
washing, the immunoprecipitates were fractionated by SDS-PAGE (10% gel), transferred to Immobilon 
P, and immunoblotted with hRad9, hHus1, or hRad1. 
 
 
 To further verify that these proteins associate, we immunoprecipitated hRad9 in K562 
cell lysates. In these precipitates we readily observed a hHus1-reactive band (Fig. 1A, right 
panel) that co-migrated with immunoprecipitated hHus1 (Fig. 1A, left panel). We also 
immunoprecipitated hRad1 and demonstrated that hHus1 (Fig. 1A, middle panel) was present 
in anti-hRad1 immunoprecipitates. However, we did not detect hRad1 protein in hRad9 
immunoprecipitates (Fig. 1B, right panel), even though we did observe hRad9 in anti-hRad1 
immunoprecipitates (Fig. 1C, middle panel). A possible explanation for these discrepant results 
is that hRad1 and the immunodominant anti-hRad9 antibodies share an overlapping binding 
site, which precludes simultaneous interaction. Alternatively, antibody binding to hRad9 
induces conformational changes of hRad9 that inhibit interaction of hRad1 and hRad9. In 
support of this, Figure 4 demonstrates that anti-AU1 immunoprecipitates of AU1-tagged 
hRad9 do contain hRad1. These results suggest that this group of human checkpoint proteins 
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as well as their yeast counterparts assembles into multimolecular complexes, even in the 
absence of genotoxic stimuli.  
 
3.2 hRad9 undergoes complex post-translational modifications 
 To generate a model system of checkpoint protein function amenable to biochemical 
analysis, we prepared epitope-tagged expression vectors for hRad9, hHus1, and hRad1. The 
cDNAs were obtained by PCR amplification from a human testes cDNA library using primers 
containing the sequence of the respective epitope. In this way, we generated hRad1 linked to a 
tandem FLAG-epitope (hRad1-FLAG2), hHus1 linked to two HA-epitopes (hHus1-HA2), and 
hRad9 linked to either an AU1-epitope (hRad9-AU1) or to GFP (hRad9-GFP). These 
expression vectors were transfected into K562 cells by electroporation, which resulted in 
transient expression of epitope-tagged protein within 16-24 hrs.  
 
 Immunoprecipitation studies (Fig. 1) revealed that, when analyzed by SDS-PAGE, 
hRad9 migrated with an apparent molecular mass that was much larger (70 kDa) than 
predicted (45 kDa), suggesting that the entire cellular pool of hRad9 may undergo extensive 
post-translational modifications. Consistent with this observation, overexpression of AU1-
tagged hRad9 revealed multiple species when resolved by SDS-PAGE (Fig. 2, lane 5). The 
major band detectable had an apparent molecular mass of 55 kDa. This is significantly smaller 
than the 70-kDa endogenous hRad9 (Fig. 2, lanes 2 and 3), but still larger than the predicted 
molecular mass (45 kDa), even when the 2-kDa epitope tag is taken into account. Thus, the 
major 55-kDa may be either an unmodified form that migrates anomalously or a partially 
modified version. In addition to the 55-kDa form, multiple slower-migrating bands were 
present above this band, suggesting several steps of post-translational modification (Fig. 2, 
lane 5). Remarkably, co-expression of hRad9-AU1 with hHus1-HA and hRad1-FLAG resulted 
in a large increase of the amount of a highly modified, 72-kDa form of hRad9. This slow-
migrating form of hRad9 had an apparent molecular mass slightly greater than endogenous 
hRad9, which is due to the addition of the tandem AU1 tag on hRad9 (Fig. 2, lane 6). Taken 
together, these results suggest that endogenous hRad9 is quantitatively and extensively 
modified. Furthermore, limiting cellular factors, possibly hRad1 and hHus1, are required for 
modification of hRad9. 
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Figure 2. Transiently overexpressed hRad9 undergoes complex modifications. K562 cells (1x107 cells 
per sample) were transiently transfected with 40 µg pcDNA3 empty vector only (lanes 1, 2, and 4), with 
5 µg pEF-BOS-∆RI-hHus1-HA2 and 5 µg pcDNA3-FLAG2-hRad1 expression vectors (lane 3), with 20 
µg AU1-hRad9 alone (lane 5), or with these amounts of pEF-BOS-∆RI-hHus1-HA2 together with 
pcDNA3-FLAG2-hRad1 and AU1-hRad9 (lane 6). In all cases empty vector was added so that all 
transfections contained a total of 40 µg DNA. The following day, cell lysate were immunoprecipitated 
with either preimmune serum (PI, lane 1), anti-hRad9 (lanes 2 and 3), or anti-AU1 mAb (lanes 4-6). 
Immunoprecipitations were fractionated by SDS-PAGE (10% gel), transferred to Immobilon P and 
blotted with anti-hRad9. The arrows indicate apparent molecular masses of AU1-hRad9 calculated 
using commercially available protein standards.  
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3.3 Co-expression of hRad1 and hHus1 enhance accumulation 
of modified hRad9 
 As observed in Figure 2, co-expression of hRad1 and hHus1 has an obvious impact on 
the accumulation of modified hRad9. To further explore the role of hRad1 and hHus1 in the 
modification of hRad9, we transfected K562 cells with a constant amount of GFP-tagged 
hRad9 along with increasing amounts of the hRad1 and hHus1 expression vectors (Fig. 3). In 
this experiment, the protein-containing membrane was immunoblotted sequentially with anti-
GFP (hRad9) antiserum (Fig. 3A), then with anti-FLAG (hRad1) antiserum (Fig. 3B), and 
finally with anti-HA (hHus1) antiserum (Fig. 3C). Between these sequential immunoblottings, 
the membrane was washed in 8 M guanidine hydrochloride solution to remove the bound 
antibody. Like hRad9-AU1, GFP-tagged hRad9 also undergoes extensive alterations in 
mobility when resolved with SDS-PAGE. In the absence of co-expressed hRad1 and hHus1 
there was little conversion of hRad9 to the most highly modified form (Fig. 3A, lane 2). As 
expression of hRad1 and hHus1 increases (Fig. 3B and C, lanes 3-6) there is concomitant 
enhanced formation of the most highly modified form of hRad9 (Fig. 3A, lanes 3-6). These 
results, coupled with the results presented in Figure 2, demonstrate that hRad1 and hHus1 
either promote formation of, or stabilize the modified form of hRad9.  
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Figure 3. hRad1 and hHus1 promote the formation of slower-migrating forms of hRad9. K562 cells 
(1x107 per sample) were transfected with pcDNA3 empty vector alone (-, lane 1) or 10 µg pcDNA3-
GFP-hRad9 (lanes 2-6), along with increasing amounts of pEF-BOS-∆RI-FLAG2-hRad1 and pcDNA3-
hHus1-HA2 (lanes 3-6). The cell lysates were then resolved by SDS-PAGE (10% gel) and 
immunoblotted sequentially (with stripping between) with anti-FLAG, anti-HA, and then with anti-GFP 
rabbit antiserum. The corresponding immunoreactive bands are indicated. The apparent molecular mass 
of GFP-hRad9 was estimated by comparisons with molecular weight standards. 
 
 
3.4 Epitope-tagged proteins hRad9, hHus1, and hRad1 associate 
in a modification-dependent manner 
 To test whether the transiently expressed checkpoint proteins serve as a functional 
model system, we asked whether the epitope-tagged proteins form complexes similar to those 
formed by endogenous proteins. We thus tested whether hRad9-AU1, hHus1-HA, and hRad1-
FLAG recapitulate complex formation of endogenous proteins as observed in Figure 1. Four 
sets of K562 cells were transfected with either empty expression vector alone, a combination 
of hRad9-AU1, hHus1-HA, and hRad1-FLAG alone, or expression vectors of all three 
proteins (Fig. 4, lanes 1-4, 5-8, 9-12, and 13-16). To detect endogenous hRad9 and epitope-
tagged hRad9 simultaneously, we performed the immunoblots using the rabbit anti-hRad9 
antiserum. Anti-hRad9 immunoblots of cell lysates (Fig. 4C, lanes 1-4) revealed that epitope-
tagged hRad9 was highly overexpressed compared to the 70-kDa endogenous hRad9 (Fig. 4C, 
lanes 3 and 4 vs. lanes 1 and 2), which was not visible on this exposure. Consistent with the 
results presented in Figures 2 and 3, there were multiple forms of AU1-tagged hRad9, and co-
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expression of hRad1 and hHus1 enhanced the accumulation of the highly modified form (Fig. 
4C, lane 15 vs. lane 16).  
 
 To assess associations among transiently expressed proteins, we immunoprecipitated 
hRad1-FLAG (Fig. 4, lanes 5-8), hHus1-HA (Fig. 4, lanes 9-12), and hRad9-AU1 (Fig. 4, 
lanes 13-16) and blotted with antisera recognizing each of the three proteins. In hRad1 
precipitates we detected epitope-tagged hRad1 (Fig. 4A, lanes 6 and 8), epitope-tagged hHus1 
(Fig. 4B, lanes 10 and 12), and both endogenous hRad9 (Fig. 4C, lane 6) and epitope-tagged 
hRad9 (Fig. 4C, lane 8). We also immunoprecipitated hHus1-HA (Fig. 4, lanes 9-12) and 
found hHus1 (Fig. 4B, lanes 10 and 12), associated hRad1 (Fig. 4A, lanes 10 and 12) and 
hRad9 (Fig. 4C, lanes 10 and 12). Again, as observed in the hRad1 (anti-FLAG) 
immunoprecipitates, endogenous and AU1-tagged hRad9 were present in the complex (Fig. 
4C, lanes 10 and 12). Strikingly, in both the hRad1 and hHus1 precipitations, only the most 
highly modified form of transfected hRad9 associated with hRad1, suggesting that the 
modification is essential for interaction with the checkpoint proteins hRad1 and hHus1. The 
effect is not specific to the AU1-tagged hRad9, as we have also observed that only highly 
modified GFP-hRad9 interacts with hHus1 and hRad1 (data not shown).  
 
 In the reciprocal experiment we observed that hRad1 (Fig. 4A, lane 16) and hHus1 
(Fig. 4B, lane 16) co-precipitated with immunoprecipitated hRad9 (Fig. 4, lanes 13-16). Unlike 
our observations with the endogenous proteins, hRad1 was detected readily in the anti-hRad9-
AU1 immunoprecipitations, thus strongly suggesting that our rabbit anti-hRad9 antiserum 
indeed masks or disrupts interaction of endogenous hRad1 and hRad9 (Fig. 1). Taken 
together, these results revealed that the epitope-tagged human checkpoint proteins hRad1 and 
hHus1 associated selectively with modified hRad9 in undamaged cells. Thus, the assembly of 
transiently expressed, epitope-tagged checkpoint proteins mimics the complex formation of the 
endogenous proteins (Fig. 1). 
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Figure 4. Transiently expressed, epitope-tagged hRad9, hHus1, and hRad1 interact. Cells (1x107 per 
sample) were transfected with 40 µg pcDNA3 (lanes 1, 5, 9, 13), 30 µg pcDNA3-AU12-hRad9 (lanes 
3, 4, 7, 8, 11, 12, 15, 16), 5 µg pEF-BOS-∆RI-hHus1-HA2 (lanes 2, 4, 6, 8, 10, 12, 14, 16) or 5 µg 
pCDNA3-FLAG2-hRad1 expression vectors. If required, the total amount of DNA (40 µg) in each 
transfection was kept constant by the addition of empty vector. 20 hrs after transfection, the cells were 
lysed, and an aliquot of each lysate was prepared for electrophoresis (lysate). The lysates were 
immunoprecipitated with anti-FLAG, anti-HA, or anti-AU1 mAb, and lysates and immunoprecipitates 
were fractionated by SDS-PAGE (10% gel) and transferred to Immobilon P. The membrane was 
immunoblotted sequentially with (C) anti-hRad9, (A) anti-Flag, followed by (B) anti-HA. Arrows 
indicate the positions of the labeled proteins. The apparent molecular mass of AU1-hRad9 was 
estimated by comparison to protein standards. 
 
 
3.5 hRad1 and hHus1 interact independently of hRad9 in vivo 
and in vitro 
 Based on studies in S. pombe, where spRad1 and spHus1 did not associate in yeast 
mutants that lack spRad9, we reasoned that hRad1 and hHus1 would not interact in the 
absence of hRad9 (Kostrub et al., 1998). To test this idea, we overexpressed hRad1 and hHus1 
together (without hRad9 overexpression) and assessed their interaction. Figure 5A 
demonstrates that even in the absence of overexpressed hRad9, hRad1 co-precipitated with 
hHus1 (Figure 5A, lower panel, lane 8), and hHus1 co-precipitated with hRad1 (Fig. 5A, 
upper panel, lane 12). This interaction appears to be specific since no hRad1-FLAG was 
detected in hHus1-HA precipitates from cells that were transfected with hHus1-HA only (Fig. 
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5A, lower panel, lane 6). Neither was hHus1-HA detected in hRad1-FLAG 
immunoprecipitates from cells that were not expressing hHus1-HA (Fig. 5A, upper panel, lane 
11). As shown in Figure 4, endogenous hRad9 was also found in a complex with 
overexpressed hRad1 and hHus1, leaving open the possibility that endogenous hRad9 may 
mediate the interaction of the overexpressed hRad1 and hHus1. Because hRad1 and hHus1 are 
highly overexpressed (data not shown), these results may indicate that these proteins interact 
without other components of the complex. To test whether hRad9 is required for hRad1 and 
hHus1 interaction, we transcribed and translated both proteins in vitro alone or in combination 
(Fig. 5B). The translation mixtures were then immunoprecipitated with anti-FLAG (hRad1) or 
anti-HA (hHus1) antibodies and resolved by SDS-PAGE. Immunoblotting of the anti-FLAG 
immunoprecipitations with anti-HA showed that hHus1-HA co-precipitated with hRad1-FLAG 
(Fig. 5B, upper panel, lane 12). Blotting of the anti-HA immunoprecipitations with anti-FLAG 
revealed that hRad1-FLAG co-precipitated with hHus1-HA (Fig. 5B, lower panel, lane 8). 
This suggests that, unlike in yeast, these proteins associate in the absence of hRad9. 
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Figure 5. hRad1 and hHus1 form a stable dimeric complex. (A) Cells (1x107 per sample) were 
transfected with pcDNA3 empty vector (lanes 1, 5, 9), pEF-BOS-∆R1-hHus1-HA2 alone (lanes 2, 6, 
10), pcDNA3-FLAG2-hRad1 alone (lanes 3, 7, 11), or both expression vectors (lanes 4, 8, 12). Cell 
lysates were prepared, and a portion was prepared for analysis by SDS-PAGE. The lysates were then 
immunoprecipitated with anti-HA or anti-FLAG mAbs. The lysates and immunoprecipitates were then 
resolved by SDS-PAGE (10% gel) and immunoblotted with anti-FLAG followed by anti-HA. The 
migration positions of the epitope-tagged proteins are indicated. (B) In vitro transcription and 
translation reactions were performed with either 1 µg pcDNA3 empty vector (lanes 1, 5, and 9), 1 µg 
pcDNA3-hHus1-HA2 alone (lanes 2, 6, and 10), 1 µg pcDNA3-FLAG2-hRad1 alone (lanes 3, 7, and 
11), or 1 µg of both pcDNA3-HA2-hHus1 and pcDNA3-FLAG2-hRad1 together (lanes 4, 8, and 12).  
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3.6 hRad9 does not associate with hHus1 or hRad1 alone 
 In S. cerevisiae, interaction of the checkpoint proteins scDdc1 (homolog of hRad9) and 
scMec3 was dependent on the presence of scRad17 (homolog of hRad1; Paciotti et al., 1998). 
We thus asked whether hHus1 interacted with hRad9 in the absence of overexpressed hRad1. 
K562 cells were transfected with empty vector alone, expression vectors for all three proteins, 
or with expression vectors for hRad9 and hHus1 alone. Immunoprecipitation of hHus1 
revealed that hRad9 (Fig. 6A, lane 5) and hRad1 (Fig. 6B, lane 5) associated with hHus1 when 
all three proteins were co-expressed. In the absence of hRad1, hRad9 did not interact with 
hHus1 (Fig. 6A, lane 6). Correspondingly, hRad9 immunoprecipitations (anti-GFP) did not 
contain hHus1 (Fig. 6C, lane 9) unless hRad1 was also expressed (Fig. 6C, lane 8). We note 
that expression levels of hHus1 (Fig. 6C, lanes 2 and 3) are not equal. This was repeatedly 
observed in experiments where hRad9 and hHus1 were co-expressed in the absence of hRad1, 
suggesting that hHus1 accumulation is by some means dependent of hRad1 expression. In 
favor of this hypothesis is the observation that spHus1 levels are significantly decreased in 
yeast mutants lacking the sprad1 gene (Kostrub et al., 1998).  
 
 We next asked whether hRad1 associated with hRad9 in the absence of co-expressed 
hHus1. Cells were transfected with empty vector only, with all three checkpoint protein 
expression vectors, or with hRad9 and hRad1 only (Fig. 7). In cells expressing all three 
proteins, both hHus1 (Fig. 7B, lane 5) and hRad9 (Fig. 7A, lane 5 and Fig. 7C, lane 8) 
associated with hRad1. hRad1 did not associate with hRad9 in cells transfected with only 
hRad1 and hRad9 (Fig. 7A, lane 6 and Fig. 7C, lane 9), even though expression levels of 
hRad1 and hRad9 were similar in both cases. Therefore, the results presented in Figures 6 and 
7 suggest that hRad1 and hHus1 form an independent molecular complex. Furthermore  they 
indicate that interaction of hRad9 with either hRad1 or hHus1 requires the presence of both 
hRad1 and hHus1. 
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Figure 6. Transiently expressed hHus1 and hRad9 alone do not interact. K562 cells (1x107 per sample) 
were transfected with pcDNA3 empty vector (lanes 1, 4, 7), the combination of 5 µg pEF-BOS-∆RI-
HA2-hHus1, 5 µg pcDNA3-hRad1-FLAG2, and 30 µg pcDNA3-AU12-hRad9 expression vector 
together (lanes 2, 5, 8), or with 5 µg pEF-BOS-∆RI-HA2-hHus1 30 µg pcDNA3-AU12-hRad9 only 
(lanes 3, 6, 9). A portion of the lysate was prepared for SDS-PAGE, and the remainder was 
immunoprecipitated with anti-FLAG or anti-GFP. The cell lysates and immunoprecipitates were 
resolved by SDS-PAGE (10% gel), transferred to Immobilon P, and immunoblotted sequentially with 
(B) anti-FLAG and (C) anti-HA mAbs, followed by immunoblotting with (A) anti-GFP antiserum.  
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Figure 7. Transiently expressed hRad1 and hRad9 alone do not interact. Log-phase K562 cells (1x107 
per sample) were transfected with pcDNA3 empty vector (lanes 1, 4, and 7), 5 µg pEF-BOS-∆RI-HA2-
hHus1, 5 µg pcDNA3-hRad1-FLAG2, and 30 µg pcDNA3-AU12-hRad9 expression vector together 
(lanes 2, 5, 8), or with 5 µg pcDNA3-hRad1-FLAG2 and 30 µg pcDNA3-AU12-hRad9 only (lanes 3, 6, 
9). A portion of the lysate was prepared for SDS-PAGE, and the remainder was immunoprecipitated 
with anti-FLAG or anti-GFP. The cell lysates and immunoprecipitates were resolved by SDS-PAGE 
(10% gel), transferred to Immobilon P, and immunoblotted sequentially with (C) anti-FLAG and (B) 
anti-HA mAbs, followed by immunoblotting with (A) anti-GFP antiserum.  
 
 
3.7 hRad9 is phosphorylated in response to DNA damage 
 DNA damage is not a requirement for interaction of the checkpoint proteins hRad9, 
hHus1, and hRad1. The S. pombe homolog of hHus1 (spHus1) is inducibly phosphorylated by 
treatment with DNA-damaging agents as a consequence of checkpoint pathway activation 
(Kostrub et al., 1998). scDdc1, the putative S. cerevisiae homolog of spRad9/hRad9 is also 
phosphorylated in response to DNA-damaging agents (Longhese et al., 1997). Because this 
phosphorylation requires the presence of other checkpoint gene products, a direct correlation 
between Ddc1 phosphorylation and activation of DNA damage checkpoints was proposed 
(Paciotti et al., 1998).  
 
 To assess, whether the human checkpoint protein hRad9 also participates in DNA 
damage-dependent phosphorylation cascades, we explored the possibility that hRad9 is also 
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phosphorylated in response to DNA damage. It is important to note that endogenous hRad9 
(although highly modified) migrates as a single band when isolated from undamaged cells. We 
noticed that the single endogenous hRad9 band (70-kDa form) exhibited a progressively 
greater reduction in electrophoretic mobility when isolated from cells irradiated with increasing 
doses of IR (Fig. 8A). We also explored the time course of the DNA damage-induced mobility 
shift. It showed that hRad9 was modified within 30 min after treatment with IR, was maximal 
at 2 hrs, and persisted for at least 6 hrs (Fig. 8B). To determine whether the mobility shift 
reflected DNA damage-induced phosphorylation of the checkpoint protein, we treated hRad9 
immunoprecipitates isolated from irradiated cells with calf intestinal phosphatase (Fig. 8C). As 
expected for phosphorylation, the DNA damage-induced mobility shift was readily reversed by 
treatment with the phosphatase. Moreover, inclusion of the phosphatase inhibitor beta-
glycerophosphate blocked the effects of the phosphatase, suggesting that effects of the 
phosphatase preparation are not the result of contaminating activities. Under identical 
conditions we did not detect any shift in electrophoretic mobility of hHus1 and hRad1, 
suggesting that these proteins remain unphosphorylated in humans following treatment with IR 
(data not shown). Viewed together, these results strongly suggest that endogenous hRad9, in 
addition to other modifications, is modified by DNA damage-induced phosphorylation. 
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Figure 8. hRad9 is phosphorylated in response to DNA damage. (A) K562 cells (1x107 per sample) 
were treated with 5, 10, 20, or 50 gy IR or were left untreated (-) and cultured for 5 hrs after 
irradiation. Cell lysates were then immunoprecipitated with anti-hRad9, resolved by SDS-PAGE (10% 
gel), transferred to Immobilon P and blotted with anti-hRad9. (B) K562 cells (1x107 per sample) were 
either treated with 50 gy IR or were left untreated (-) and cultured for 0.5, 1, 2, 4.5, or 6.5 hrs. Cell 
lysates were then prepared and processed as in (A). (C) Exponentially growing K562 cells (1x107 per 
sample) were treated with 0 (-) or 50 gy (+) IR, cultured for 5 hrs, and lysed. The lysates were 
immunoprecipitated with anti-hRad9. The immunoprecipitates were then washed with lysis buffer, 
followed by phosphatase buffer, and treated with 0.25 units calf intestinal alkaline phosphatase or were 
left untreated, in the absence and presence of 50 mM β-glycerophosphate, as indicated, for 30 min at 
30°C. After phosphatase treatment the immunoprecipitates were washed once with lysis buffer, mixed 
with SDS-PAGE sample buffer, and resolved by SDS-PAGE (10% gel). 
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3.8 Phosphorylated hRad9 interacts with hHus1 and hRad1 
 Phosphorylation of the S. pombe checkpoint protein spHus1 in response to treatment 
with DNA-damaging agents does not alter spHus1’s ability to bind to spRad1 (Kostrub et al., 
1998). Likewise, phosphorylation of the S. cerevisiae hRad9 homolog (scDdc1) does not 
affect its interaction with the checkpoint protein scMec3 (Paciotti et al., 1998). We thus 
investigated whether IR-inducible hRad9 phosphorylation affects its binding to the hHus1-
hRad1 complex. Figure 9 shows non-phosphorylated hRad9 from untreated cells (Fig. 9, lane 
1) in comparison to phosphorylated hRad9 from cells treated with IR (Fig. 9, lane 2). 
Immunoprecipitation of hHus1 and hRad1 from non-irradiated cells and subsequent blotting 
with anti-hRad9 antiserum revealed association with hRad9 (Fig. 9, lanes 3 and 4) as observed 
in Figure 1. Immunoprecipitation of hRad1 and hHus1 from cells that were irradiated similarly 
yielded associated hRad9 protein (Fig. 9, lanes 5 and 6). All of the hRad9 detected appeared to 
be shifted, suggesting that the majority of the cellular hRad9 pool becomes phosphorylated in 
response to IR. These data further suggest that DNA damage does not alter the stoichiometry 
of the hRad9, hHus1, and hRad1 interaction. 
 
 
Figure 9. Phosphorylated hRad9 interacts with hHus1 and hRad1. K562 cells (1x107 per sample) were 
treated with 0 (-) or 50 gy (+) IR and cultured for 5 hrs after irradiation. Cell lysates were then 
immunoprecipitated with anti-hRad9 (lanes 1 and 2), with anti-hHus1 (lanes 3 and 5), or with anti-
hRad1 (lanes 4 and 6), resolved by SDS-PAGE (10% gel), transferred to Immobilon P and blotted with 
anti-hRad9.  
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3.9 UV light induces moderate phosphorylation of hRad9 in 
K562 cells 
 Many checkpoint genes were identified by genetic analysis of radiosensitive yeast 
mutants (Elledge, 1996; Paulovich et al., 1997). S. pombe with mutant sprad9 are sensitive to 
IR as well as to ultraviolet (UV) light, suggesting that spRad9 carries out functions in IR- and 
UV light-induced DNA damage responses. Expression of hRad9 in spRad9 mutant yeast did 
not complement UV light sensitivity or the UV-inducible G2-M checkpoint. In contrast, human 
Rad9 partially restored the survival of a G2-M checkpoint-defective S. pombe strain lacking 
spRad9 (Lieberman et al., 1996). This suggests that the human Rad9 protein may have lost its 
function in UV-induced damage response in humans. To test whether UV light induces 
phosphorylation of hRad9, and thus activates hRad9-dependent damage responses, we 
irradiated K562 cells with increasing doses of UV light and analyzed hRad9’s ability to 
undergo phosphorylation. Whereas IR induced phosphorylation of most of the cellular hRad9 
pool (Fig. 10, lane 2), UV irradiation generates only moderate phosphorylation of the hRad9 
protein (Fig. 10, lanes 3-5), suggesting that additional mechanisms regulate the response to 
DNA damage induced by UV light in human cells. 
 
 
 
Figure 10. UV light induces only marginal phosphorylation of hRad9 in K562 cells. K562 cells (1x107 
per sample) were treated with 0 (-) or 50 gy IR, or with 40, 150, and 300 J/cm2 and cultured for 5 hrs 
after irradiation. Cell lysates were then immunoprecipitated with anti-hRad9, resolved by SDS-PAGE 
(10% gel), transferred to Immobilon P and blotted with anti-hRad9. 
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3.10 γ-irradiation induces phosphorylation of hRad9 in human 
keratinocytes 
 The human skin is the main target organ of UV radiation. Keratinocytes must therefore 
have potent protective mechanisms preventing radiation-induced DNA damage. This notion 
raised the question whether phosphorylation of hRad9 occurs in human keratinocytes as 
observed in K562 cells. 
 
 To address this we irradiated human keratinocytes and K562 cells with IR and UV light 
and explored hRad9’s ability to undergo phosphorylation (Fig. 11). hRad9 extracted from γ-
irradiated keratinocytes had reduced mobility relative to non-irradiated cells (Fig. 11A, lane 1 
vs. lane 2), which demonstrates that IR induces hRad9 phosphorylation in keratinocytes. In 
contrast, escalating doses of UV light did not shift hRad9’s mobility in human keratinocytes 
(Fig. 11A, lanes 3-5), suggesting that this modification of hRad9 is not actively involved in 
UV-induced DNA damage response in this cell type. 
 
 To further analyze the phosphorylation of hRad9 observed after γ-irradiation in human 
keratinocytes, keratinocytes were exposed to increasing doses of IR and migration 
characteristics of hRad9 were examined (Fig. 11C). Unlike with K562 cells, higher doses of IR 
are required to fully shift hRad9 in keratinocytes (Fig. 7A). The time-course experiment 
demonstrates that hRad9 phosphorylation peaks as early as 1 hr after irradiation and decreases 
within the following 2 to 3 hrs (Fig. 11B). Thus, in keratinocytes hRad9 is more rapidly 
phosphorylated than in K562 cells, and this response is shorter lived than in K562 cells (Fig. 
8B). These data suggest that the hRad9 phosphorylation in response to IR is a physiological 
reaction in human keratinocytes and probably other human tissue types as well. Because hRad9 
phosphorylation cannot be induced by UV light in human keratinocytes, other pathways are 
proposed to respond to UV-induced DNA damage, especially in keratinocytes. 
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Figure 11. γ-irradiation - but not UV light - induces phosphorylation of hRad9 in human keratinocytes. 
(A) Human keratinocytes (5x106 per sample) were treated with 0 (-) or 50 gy IR, or with 40, 150, and 
300 J/cm2 UV light and cultured for 5 hrs after irradiation. Cell lysates were then immunoprecipitated 
with anti-hRad9, resolved by SDS-PAGE (10% gel), transferred to Immobilon P and blotted with anti-
hRad9. (B) Human keratinocytes (5x106 per sample) were treated with 50 gray IR and cultured for 0, 1, 
2, 4, or 6 hrs. Cell lysates were then immunoprecipitated with anti-hRad9, resolved by SDS-PAGE 
(10% gel), transferred to Immobilon P and blotted with anti-hRad9. (C) Human keratinocytes (5x106 
per sample) were treated with 0 (-), 5, 10, 20, or 50 gy IR and cultured for 5 hrs after irradiation. Cell 
lysates were then immunoprecipitated with anti-hRad9, resolved by SDS-PAGE (10% gel), transferred 
to Immobilon P and blotted with anti-hRad9. 
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3.11 Epitope-tagged hRad9 is located in the nucleus 
 The previous data in combination with earlier studies in the yeasts S. pombe and S. 
cerevisiae support the idea that biochemical functions of hRad9 are conserved from lower 
eucaryotes to humans (Lieberman et al., 1996). The hRad9 homologs spRad9 (in S. pombe) 
and scDdc1 (in S. cerevisiae) are both components of checkpoint pathways activated by DNA 
damage (Longhese et al., 1997). Genetic and biochemical studies indicate that both spRad9 
and scDdc1 function in close proximity to or directly in DNA damage detection, suggesting 
that these proteins may be located in the nucleus (Weinert, 1998; Longhese et al., 1998; 
Paciotti et al., 1998). 
  
 To assess where in the cell hRad9 is located, we transiently transfected K562 cells with 
either empty vector (Fig. 12A), green fluorescent protein (GFP) alone (Fig. 12B), or GFP-
tagged hRad9 (Fig. 12C). The nuclei were counter-stained with the DNA-binding dye 
propidium iodide (PI), and cells were then analyzed using a confocal laser scanning 
microscope. In cells transfected with empty vector alone (Fig. 12A), the DNA-binding PI stain 
marked the nucleus (red). In cells transfected with GFP alone (Fig. 12B), GFP (green) was 
localized throughout the nucleus and the cytoplasm without any distinctive pattern. In contrast, 
cells transfected with hRad9-GFP (Fig. 12C) displayed a characteristic distribution of GFP-
tagged hRad9, which was localized predominantly inside of the nucleus. Furthermore, we 
observed that GFP-tagged hRad9 was excluded from the nucleoli. Together, these results 
suggest that hRad9 is a nuclear protein, consistent with a proximal role in the detection of 
DNA damage or the relay of DNA damage-induced signals.  
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Figure 12. Epitope-tagged hRad9 is located in the nucleus. K562 cells (5x106 per sample) were 
transfected with (A) empty vector, (B) 5 µg GFP alone, or (C) 5 µg GFP-tagged hRad9. Approximately 
15000 cells of each sample were spun down on a microscopical coverslip and fixed with 4% 
paraformaldehyde in PBS for 3 min. Nuclei were counter-stained for 3 min with 10 µl/ml propidium 
iodide (PI) in PBS. Coverslips were air-dried and mounted on microscopic slides with Vectashield 
Antifade mounting medium. Fluorescent microscopy was performed using the Confocal laser scanning 
microscope LSM510. Images were created with the LSM510 software for windows NT and saved as 
TIFF files. 
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4 Discussion 
 The discovery of radiosensitive yeast mutants led to the cloning of the mutated genes 
(Rowley et al., 1992; al-Khodairy and Carr, 1992; Enoch et al., 1992). Some of these genes 
are clearly involved in DNA repair (Game, 2000). Others, dubbed checkpoint genes, 
participate in regulation of cell cycle control after DNA damage (Elledge, 1996; Paulovich et 
al., 1997). Their identification brought about a new paradigm of DNA damage response 
mechanisms in eucaryotes termed cell cycle checkpoints (Hartwell and Weinert, 1989). 
Checkpoints are signaling cascades that halt the cell cycle in response to DNA damage, thereby 
providing time for repair and preventing accumulation of DNA alterations. Thus, the 
coordination of checkpoint activation and DNA repair promotes genomic integrity throughout 
the cell cycle (Weinert, 1998; Elledge, 1996). 
 
 The recent identification of human homologs of yeast checkpoint proteins fueled 
speculation that the pathways regulating checkpoints may be conserved from yeast to humans 
(Udell et al., 1998; Savitsky et al., 1995; Lieberman et al., 1996; Parker et al., 1998; Kostrub 
et al., 1998; Sanchez et al., 1997). Checkpoint defects may generate genomic instability, which 
is characteristic and even diagnostic of virtually all human cancers (Elledge, 1996; Weinert, 
1998; Longhese, 1998). In fact, some heritable instability syndromes that share predisposition 
to cancer as a common feature have defects in checkpoint-regulating genes, suggesting that 
intact checkpoint controls are crucial to prevent genomic instability and cancer (Kastan et al., 
1995; Tainsky et al., 1995; Hoekstra, 1997). Although human homologs of checkpoint-
regulating genes were identified, the physical and functional roles of many of these proteins are 
largely unexplored, even in the well-studied yeast systems. 
 
 The impact of checkpoint defects on genomic instability and carcinogenesis as well as 
the possibility to therapeutically exploit checkpoint defects in common cancers raises interest in 
the molecular mechanisms underlying checkpoint function. To gain insight into the functions of 
human checkpoint proteins, we have undertaken a biochemical and cellular analysis of the 
novel checkpoint proteins hRad9, hHus1, and hRad1. We show that hRad9 is a nuclear 
protein, which undergoes complex post-translational modifications in undamaged cells and is 
inducibly phosphorylated in response to DNA damage, indicating that this protein participates 
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in a DNA damage-inducible signaling pathway in humans. We also demonstrate that fully 
modified hRad9 interacts with hHus1 and hRad1 in a stable multimolecular complex that is 
present in damaged and even in undamaged cells. Unlike IR, our studies reveal that UV light 
only modestly induces hRad9 phosphorylation in K562 cells. In human keratinocytes, hRad9 is 
not phosphorylated in response to UV irradiation. These results demonstrate that hRad9, 
hHus1, and hRad1 form a stable IR-responsive checkpoint complex that actively participates in 
human cellular responses to DNA damage in K562 cells as well as in human keratinocytes. 
 
4.1 A multi-component human checkpoint complex 
 Epistasis studies identify genetic interactions and are frequently indicative of 
biochemical interactions as well. Such studies in S. cerevisiae have shown genetic and 
biochemical interactions among the members of the scrad24 epistasis group, which includes S. 
cerevisiae homologs for hRAD1 (scrad17), hRAD17 (scrad24), and hRAD9 (scddc1; 
Longhese et al., 1997; Lydall and Weinert, 1995; Eckardt-Schupp et al., 1987). In addition, 
previous work demonstrated that spRad1 and spHus1 interacted in the fission yeast S. pombe 
(Kostrub et al., 1998). Although these studies demonstrated that spHus1 and spRad1 required 
spRad9 for interaction, which suggested that spRad9 might directly or indirectly tether the 
molecules, this possibility was not directly tested. 
 
 Using specific immunological reagents, our results demonstrate for the first time that 
the human proteins hRad9, hHus1, and hRad1 interact in a trimolecular complex. In contrast to 
previous studies in S. pombe, our studies suggest that hRad1 and hHus1 associate in the 
absence of hRad9. Several groups have since confirmed the interaction of these three proteins 
in cell lysates (St Onge et al., 1999; Caspari et al., 2000), in yeast two-hybrid systems (St Onge 
et al., 1999; Hang and Lieberman, 2000), in insect cells (Burtelow et al., 2001), and in vitro 
(Lindsey-Boltz et al., 2001; Griffith et al., 2002).  
 
 Because in our studies overexpressed, epitope-tagged hRad1 and hRad9 did not 
associate in the absence of co-expressed hHus1, and likewise, hHus1 and hRad9 could not 
associate without hRad1, we speculated that hRad1 and hHus1 alone form a heterodimeric 
complex that interacts with hRad9. Lately, reconstitution of the complex in insect cells 
revealed that each of the three members of the complex interacts with any other complex 
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member in a pair-wise manner, even without co-expression of the third binding partner. 
Mapping of the interaction domains indicated that the amino terminus of hRad9 interacts with 
the carboxyl terminus of hRad1, the amino terminus of hRad1 interacts with the carboxyl 
terminus of hHus1, and the amino terminus of hHus1 interacts with the carboxyl terminus of 
hRad9, suggesting that the three proteins form a ring-like structure (Burtelow et al., 2001). 
Given that we used overexpressed, epitope-tagged protein for our interaction studies, it seems 
likely that our epitope tags or the antibodies may have disrupted the interactions between 
hRad1 and hRad9 as well as between hHus1 and hRad9. Together, our results demonstrate 
that hRad9, hHus1, and hRad1 form a trimolecular complex in human cells. Furthermore, they 
suggest that human checkpoint complexes may be differentially assembled as compared to 
complexes in yeast cells, indicating that specific details in checkpoint function have changed, 
whereas general functions are conserved from yeast to humans. 
 
4.2 hRad9 is extensively modified 
 The present studies revealed that endogenous hRad9 migrates with an apparent 
molecular mass of 70 kDa, whereas its predicted molecular mass is 45 kDa. Because 
endogenous hRad9 migrates anomalously even when isolated from untreated cells, the 
modification likely occurs in the absence of DNA damage. Initial insight into the discrepancy 
came from studies showing that expression of epitope-tagged hRad9 alone yielded a protein 
that migrated primarily as a 55-kDa band. Although the 55-kDa band is significantly larger 
than the predicted molecular mass (even when the 2-kDa epitope tag is taken into account), we 
could not determine whether this band represented an unmodified or partially modified form of 
hRad9.  
 
 Even more intriguing is the observation co-expression of hRad1 and hHus1 leads to the 
appearance of greater amounts of fully shifted protein. One possible explanation for this result 
is that hRad1 and hHus1 are required for hRad9 modification. Another, perhaps more plausible 
explanation is that hRad9 is not stable when overexpressed singly, but once it associates with 
hRad1 and hHus1 it forms a stable multimolecular complex. In support of this possibility, 
AU1-tagged hRad9 expresses less well than hRad9 fused to the large and stable GFP moiety. 
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It is more difficult to detect intermediate forms of modified AU1-hRad9 than of GFP-hRad9 
(Karnitz, personal communication). 
 
 There is precedence for other checkpoint proteins undergoing extensive modifications 
that dramatically alter their apparent molecular mass and regulate their interactions with other 
proteins. For example, the unrelated scRad9 is phosphorylated in undamaged cells, and this 
modification is essential for scRad9’s interaction with the checkpoint protein kinase scRad53 
(Sun et al., 1998; Vialard et al., 1998). There are several potential molecular modifications that 
may contribute to hRad9’s mobility shift, including phosphorylation. In fact, recent studies 
demonstrated that the anomalous migrating behavior of hRad9 is due to constitutive 
phosphorylation (Chen et al., 2001; St Onge et al., 2001). Apparently, high concentrations of 
phosphatase are necessary in order to achieve full reversal of this type of hRad9 
phosphorylation, yielding a 45-kDa band representing unmodified hRad9. Our studies used low 
concentrations of phosphatase, which only reversed the inducible (hyper-) phosphorylation in 
response to IR. Thus, in addition to being inducibly phosphorylated in response to DNA 
damage, hRad9 is constitutively phosphorylated in the absence of genotoxic stress.  
 
 Several sites of constitutive phosphorylation have now been identified within the 
carboxyl terminus of the hRad9 protein (Roos-Mattjus et al., 2003; St Onge et al., 2003). By 
mutating the constitutively phosphorylated amino acids of hRad9 to alanins, it has been shown 
that constitutive hRad9 phosphorylation promotes cell survival when cells are exposed to 
genotoxic stress. Cells defective in constitutive hRad9 phosphorylation are unable to induce 
activation of Chk1 in response to genotoxins and are thus unable to induce Chk1-mediated 
checkpoint responses, indicating that hRad9’s C-terminus is a regulatory region for effector 
functions of the hRad9-hHus1-hRad1 complex (Roos-Mattjus et al., 2003).  
 
4.3 hRad9 is part of a DNA damage-responsive complex 
 Previous studies in yeast demonstrated that hRad1 and hHus1 genetically and 
biochemically interact and are required for activation of checkpoints in response to DNA 
damage and replication inhibitors (Kostrub et al., 1998). Although much genetic evidence 
attests to their importance in cell cycle arrest and survival, even in the well-studied yeast 
models little is known about their functions. spRad1 and hRad1 have significant homology 
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with Ustilago maydis Rec1, a putative exonuclease (Udell et al., 1998; Parker et al., 1998; 
Freire et al., 1998). Additionally, hRad1 and hRad9 may possess 3’ to 5’ exonuclease activity 
(Bessho and Sancar, 2000; Parker et al., 1998). The presence of DNA-metabolizing proteins in 
the multimolecular complex, coupled with genetic data that place spRad9, spHus1, and 
spRad1, and their S. cerevisiae counterparts early in the response pathway, suggests that the 
complex may function as a sensor that scans the genome for damaged DNA (Weinert, 1998; 
Longhese et al., 1998; Paciotti et al., 1998). Once damaged DNA is detected, this complex 
may initiate endonucleolytic processing of the lesions and trigger interactions with downstream 
signaling elements. Alternatively, the checkpoint complex may link unknown damage 
recognition components to downstream signal-transducing pathways that include ATM and 
hChk1, both of which are implicated in actively enforcing cell cycle arrest after DNA damage 
(Carr, 1996; Weinert, 1997).  
 
 The present results support an early role for hRad9 in evolutionarily conserved DNA 
damage-induced signaling cascades. In addition to being constitutively phosphorylated in the 
absence of DNA damage, a process required for activation of Chk1 (Roos-Mattjus et al., 
2003), hRad9 is inducibly phosphorylated in response to IR (Volkmer and Karnitz, 1999; St 
Onge et al., 1999). Likewise, the yeast checkpoint protein scDdc1 (homolog of spRad9 and 
hRad9) is phosphorylated in response to IR (Longhese et al., 1997). scDdc1 phosphorylation 
requires MEC1, an ATM homolog (Paciotti et al., 1998), suggesting that scDdc1/hRad9 may 
be a key regulator of the complex. Interestingly, it was recently shown that IR-inducible hRad9 
phosphorylation occurs on Ser272 and that this event is mediated by the checkpoint kinase 
ATM. Overexpression of hRad9-Ser272A mutant protein in human fibroblasts induces an 
increased sensitivity to IR and disturbs G1-S checkpoint induction, suggesting that hRad9 also 
participates in an IR-induced, ATM-mediated checkpoint activation (Chen et al., 2001). 
 
 Consistent with an early function in DNA damage response, the hRad9-hHus1-hRad1 
complex has recently been shown to associate with chromatin after DNA damage (Burtelow et 
al., 2000). Furthermore, under refined experimental conditions, it could be demonstrated that 
the trimolecular complex interacts with hRad17, one of the six proteins that regulate 
checkpoint responses S. pombe (Rauen et al., 2000). Interestingly, hRad17 has extensive 
homology with all five subunits of replication factor C (RFC; Parker et al., 1998; Griffith et al., 
  
 
59
2002). RFC is a heteropentameric protein complex composed of one large (p140) and four 
smaller (p36, p37, p38, p40) subunits (Stillman, 1994). Competing with the largest subunit, 
hRad17 forms a complex with the four smaller RFC subunits (Lindsey-Boltz et al., 2001). It is 
well established that the original RFC complex loads proliferating cell nuclear antigen (PCNA), 
a trimolecular ring-like sliding clamp, onto DNA in a clamp-clamp loader-like fashion, which 
then tethers protein kinase C δ to DNA during DNA synthesis (Waga and Stillman, 1998). 
Based on biochemical data indicating that hRad9, hHus1, and hRad1 form a trimolecular 
complex in vivo (Volkmer and Karnitz, 1999; St Onge et al., 1999) with a putative ring-like 
structure (Burtelow et al., 2001), in combination with molecular modeling studies, which, 
based on sequence homology of each of the three complex members with PCNA, predicted 
that the hRad9-hHus1-hRad1 complex resembles PCNA, it has been suggested that hRad17-
RFC may load the hRad9-hHus1-hRad1 ring onto DNA analogously to RFC and PCNA 
(Venclovas and Thelen, 2000; Caspari et al., 2000). Indeed, it could be demonstrated that the 
binding of the hRad9-hHus1-hRad1 complex to chromatin in response to DNA damage 
requires the presence of hRad17 (Zou et al., 2001) and, just recently, electron microscopic 
evidence was provided demonstrating that hRad17 recruits the hRad9-hHus1-hRad1 complex 
onto DNA in an ATP-dependent manner, suggesting that hRad17 may be the sensor of DNA 
damage, which then loads the checkpoint complex onto sites of damaged DNA (Bermudez et 
al., 2003). Taken together, the present data provide the first identification of a DNA damage-
responsive human checkpoint complex that is fundamentally conserved between yeast and 
humans.  
 
4.4 UV light is not a potent activator of hRad9 phosphorylation 
 Many checkpoint proteins were identified by genetic analysis of yeast mutants that 
were hypersensitive to genotoxic agents (Elledge, 1996; Paulovich et al., 1997). S. pombe rad9 
mutants are sensitive to IR, UV light, and hydroxyurea (HU). The human Rad9 protein, if 
expressed in an S. pombe rad9 mutant strain, partially restores the IR-induced checkpoint 
responses and restores HU-induced checkpoint responses to nearly wild-type levels 
(Lieberman et al., 1996). These findings strongly suggest functional conservation of hRad9 
from yeast to humans, at least in the HU- and IR-induced checkpoint response. Expression of 
hRad9 in spRad9 mutant yeast did not complement UV light-induced checkpoint delay at the 
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G2-M border (Lieberman et al., 1996). This may suggest that the Rad9 protein has lost its 
function in UV-induced damage response in humans. To test whether hRad9 participates in 
UV light-induced checkpoint response in humans, we irradiated K562 cells with increasing 
doses of UV light and analyzed whether UV induced hRad9 phosphorylation. Even at high 
doses, UV light only partially shifted hRad9’s mobility. In marked contrast, UV light did not 
induce phosphorylation of hRad9 in keratinocytes, whereas IR did cause hRad9 
phosphorylation in these cells. 
 
 These data suggest that hRad9 phosphorylation in response to IR is a physiological 
reaction in human keratinocytes and probably all other human tissue types as well. As UV light 
in human keratinocytes cannot trigger inducible phosphorylation other pathways are likely to 
respond to UV-induced DNA damage in these cells. We propose that keratinocytes, which are 
constantly exposed to UV light, may have evolved highly efficient mechanisms to immediately 
manage UV-induced DNA damage before checkpoint mechanisms are activated. In support of 
this hypothesis, inducible phosphorylation of hRad9 has been implicated in ATM-mediated 
checkpoint activation in response to IR, but not UV light, suggesting that hRad9 is not 
involved in UV-induced checkpoint responses (Chen et al., 2001). However, constitutive 
phosphorylation of hRad9 is required for activation of Chk1 in response to UV light, but not 
IR, indicating that different portions of hRad9 are involved in different checkpoints, which are 
activated by different types of DNA damage (Roos-Mattjus et al., 2003).  
 
4.5 Checkpoint genes are potential candidates for tumor 
suppressor genes  
 While dominant-acting oncogenes can be activated by single mutations in one allele, 
tumor suppressor genes are usually recessive and require inactivating mutations in both alleles 
to develop their carcinogenic potential (Aaronson, 1991). Tumor suppressors may also cause 
hereditary cancer predisposition. An individual that is carrier of a defective allele in a tumor 
suppressor is phenotypically normal but has an increased risk to develop cancer because only 
one mutation in the remaining allele is necessary to inactivate the gene (Sherr, 1996). In these 
individuals, a single mutation in a tumor suppressor may be silent for years. This main 
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characteristic identifies tumor suppressors: genes that are required for normal cell function, and 
when defective initiate cancer development.  
 
 Interestingly, tumor suppressor gene products usually impose constraints on cell cycle 
progression or cell growth. Loss-of-function mutations release the constraints and 
subsequently promote genomic instability and carcinogenesis, which is consistent with a 
function in cell cycle checkpoints (Jacks and Weinberg, 1996). In fact, the classical tumor 
suppressor genes encode components of cell cycle checkpoints. Moreover, they are frequently 
mutated and lost in human cancers, suggesting that mutations of these stability genes during 
tumorigenesis may trigger cancer development (Donehower, 1997). To date, approximately 
ten tumor suppressor genes are known; the best characterized are p53 and RB. Others, like the 
ATM or the BRCA1 gene, are under investigation. Germ-line mutations within p53 or ATM 
cause the hereditary diseases Li-Fraumeni (LF) and ataxia telangiectasia (AT), which provoke 
genomic instability and were therefore termed instability syndromes (Kastan et al., 1995; 
Tainsky et al., 1995; Hoekstra, 1997). Germ-line mutations of the breast cancer susceptibility 
gene 1 (BRCA1) predispose women to breast and ovarian cancer. A role for this gene in DNA 
repair has been proposed recently, but BRCA1 may also be involved in cell cycle checkpoint 
control (Feunteun and Lenoir, 1996; Xu et al., 1999; Paterson, 1998). It remains unclear, 
whether BRCA1’s role in DNA repair or its role in cell cycle control or a combination of the 
two is responsible for the elevated risk of cancer. These studies indicate that disruption of 
DNA damage-activated cell cycle arrest may lead to increased cancer susceptibility as known 
for defects in DNA repair mechanisms.  
 
 The results of this study support the assumption that hRad9, hHus1, and hRad1 are 
important players in a signaling cascade that leads to cell cycle arrest. Given that hRad9, 
hHus1, and hRad1 have central roles in checkpoint activation, the absence of functional gene 
products would interrupt the downstream pathway and may impede checkpoint activation and 
thereby induce genomic instability. As a consequence, the rate of acquisition of mutations 
could increase dramatically and cause cancer, similar to defects in ATM or p53. An 
appropriate way to find out whether they are tumor suppressor genes would be to screen 
tumor cell populations for expression mutations. In fact, mutated hRad17, another checkpoint 
protein, is overexpressed in human non-small cell lung cancer cells, suggesting a role for 
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hRAD17 in tumor development (Sasaki et al., 2001). Although no mutations have yet been 
found in hRAD9, hHUS1, and hRAD1, studies in fission yeast show that lack of spRad1, 
spRad9, or spHus1 abolishes the G2 checkpoint, which induces increased sensitivity to 
genotoxic agents (Carr, 1994; Paulovich et al., 1997). Interestingly, the 11q 13 region, in 
which hRad9 resides, exhibits loss of heterozygosity in human cancers. At least two tumor 
suppressor loci were mapped to that region. The most prominent gene is MEN1, which is 
responsible for type 1 endocrine neoplasia. Fine resolution mapping data suggested that 
hRAD9 is not the origin of this cancer syndrome (Lieberman et al., 1996). The presence of a 
second tumor suppressor locus in that region is suggested by studies on cervical cancer cell 
lines, and hRAD9 remains a possible candidate for this tumor suppressor gene (Lieberman et 
al., 1996). In like manner, hRAD1 has been mapped to a region that is associated with a tumor 
suppressor locus in human lung and bladder cancer (Parker et al., 1998; Marathi et al., 1998). 
These data suggest that hRAD9, hRAD1, and possibly other human checkpoint genes may act 
as tumor suppressor genes analogous to p53 and ATM. Further experiments, particularly the 
cloning of the homologous mouse cDNA and generation of knock out mice and tumor cell 
screens, will clarify this issue. 
 
4.6 Therapeutic exploitation of checkpoint research: 
Perspectives for checkpoint-based cancer therapy 
 The identification of key participants in the DNA damage checkpoint pathway raises 
the possibility of the development of checkpoint-based chemotherapy. More than 50% of all 
human malignant tumors contain mutated p53, and p53-deficient (p53-) tumor cells lack a 
DNA damage-induced G1-S checkpoint (Lutzker and Levine, 1996). Loss of p53 function also 
has variable effects on radiosensitivity and chemosensitivity. In some p53- tumor cell lines, 
genotoxic agents do not induce apoptosis resulting in decreased sensitivity to γ-irradiation or 
chemotherapeutics compared to normal cells (Kastan et al., 1995). In many other cases, loss of 
p53 has no effect on the sensitivity of a tumor cell to γ-irradiation (Lutzker and Levine, 1996). 
One emerging hypothesis is that pharmacological agents that disrupt the G2 checkpoints would 
preferentially radiosensitize p53- (G1-S checkpoint-lacking) tumor cells by disrupting 
potentially compensating G2 checkpoints (Powell et al., 1995). In fact, selective G2 
checkpoint abrogators like methylxanthines (caffeine and pentoxifylline) selectively increased 
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killing of p53-deficient tumor cells by γ-irradiation (Russel et al., 1996). Unfortunately, 
efficient doses of caffeine are too toxic for human therapy, and tolerable plasma levels of 
pentoxifylline are well below doses that suffice for G2 checkpoint abrogation in vitro. Another 
selective G2 checkpoint abrogator, UCN-01 (7-hydroxystaurosporine), is currently undergoing 
clinical trials for cancer treatment (Sausville et al., 2001). It was shown that this drug increased 
killing of p53-deficient tumor cells by γ-irradiation (Wang et al., 1996). Interestingly, the G2 
checkpoint abrogation is mediated by inhibition of Chk1, one of the conserved fission yeast 
checkpoint proteins, suggesting that other checkpoint proteins may be targets for drugs in 
cancer therapy as well (Busby et al., 2000; Graves et al., 2000). 
 
 To devise other rational ways to intervene with checkpoint-based chemotherapy, we 
need to understand the mechanism of checkpoint activation. This study provides an initial step 
towards the elucidation of checkpoint function in humans. Given that hRad9 is a key regulator 
of G2 checkpoints in humans as suggested by corresponding studies in yeast, and hRad9 
phosphorylation is the initiating step to promote checkpoint activation, it may suffice to block 
the kinase that phosphorylates hRad9 to inhibit G2 checkpoint activation. Inhibition of hRad9 
phosphorylation may thus serve to abrogate G2 checkpoint activation and enhance killing of 
p53-deficient tumor cells. A screen for substances blocking hRad9 activation could provide a 
broad spectrum of potential chemotherapeutics of use in checkpoint-based therapy. Although 
these projects will require extensive efforts in the future, the discoveries presented here 
support checkpoint research fundamentally to unravel the underlying mechanisms. This may 
help to facilitate the identification of new strategies in cancer therapy. 
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5 Summary 
Human cells have evolved protective mechanisms such as DNA repair and cell cycle 
checkpoints in order to promote stability of the genome. Studies on hereditary instability 
syndromes associated with a higher incidence of malignancies like Xeroderma pigmentosum or 
Nijmegen breakage syndrome demonstrated that genetic defects and subsequent dysfunction of 
a specific DNA repair mechanism trigger the development of cancer. Within the last years, the 
investigation of cell cycle checkpoints gained increasing importance in cancer research. 
 
 Checkpoints are signaling cascades that halt the cell cycle in response to DNA damage, 
thereby providing time for repair and preventing accumulation of DNA alterations. While the 
p53-dependent G1-S checkpoint has been extensively investigated, little is known about other 
checkpoints in humans such as the G2-M or the S-phase progression checkpoint. Studies on 
the human cancer syndrome ataxia telangiectasia (AT) showed that AT cells fail to induce 
several checkpoints in response to ionizing radiation (IR), indicating that a checkpoint gene 
defect is responsible for the AT-associated cancers. The responsible gene (ATM) has 
significant sequence homology to the checkpoint kinase gene sprad3 in the fission yeast 
Schizosaccharomyces pombe (S. pombe). In S. pombe, spRad3 regulates G2-M checkpoint 
activation in response to DNA damage. Defects in the sprad3 gene, like defects in ATM, 
sensitize the organisms to radiation and radiomimetic drugs, suggesting conservation of 
checkpoint pathways from yeast to humans as well as a potential role of the G2-M checkpoint 
in carcinogenesis. 
 
 The discovery of G2-M checkpoint-deficient yeast mutants led to the cloning of 
additional checkpoint genes in yeast and their human homologs. This group of novel human 
genes includes homologs of sprad9 (hRAD9), sphus1 (hHUS1), and sprad1 (hRAD1). In S. 
pombe, these genes are required for activation of spRad3, and defects in one or more of these 
genes render the yeast more sensitive to genotoxic agents. Mutations within the human rad 
genes may bring about an increased rate of mutations and genomic instability as shown for p53 
or AT and may be responsible for inherited predisposition to cancer. 
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 In view of this potential importance of human rad genes in the process of 
carcinogenesis, we have undertaken a cellular and molecular analysis of the novel human 
checkpoint proteins hRad9, hHus1, and hRad1 in the leukemia cell line K562 and in human 
keratinocytes. Using specific antibodies to the hRad9, hHus1, and hRad1 proteins we 
demonstrated with co-immunoprecipitation and Western-blot experiments that the human 
checkpoint proteins hRad9, hHus1, and hRad1 associate in a biochemical complex similar to 
the spRad9-spHus1-spRad1 complex reported in fission yeast. 
 
 To generate a model system of checkpoint protein function amenable to biochemical 
analysis, we prepared epitope-tagged expression vectors for hRad9, hHus1, and hRad1, which 
were transfected into K562 cells by electroporation, resulting in transient expression of 
epitope-tagged protein. By simultaneous expression of hRad9, hHus1, and hRad1 we showed 
that transiently expressed epitope-tagged checkpoint proteins hRad9, hHus1, and hRad1 
recapitulate complex formation of endogenous proteins. Immunoprecipitation studies with 
lysates of hRad9-overexpressing cells revealed that hRad9 undergoes complex post-
translational modifications. Co-expression of hRad9 with hHus1, and hRad1 resulted in a large 
increase of the amount of a highly modified form of hRad9, suggesting that hRad1 and hHus1 
either promote formation of, or stabilize the modified form of hRad9.  
 
 Previously, a direct correlation between checkpoint protein phosphorylation and 
activation of DNA damage checkpoints in yeast was proposed. In this study, we show that 
hRad9 is phosphorylated in response to DNA damage, and that phosphorylated hRad9 
interacts with hHus1 and hRad1 as well. The present results suggest that the hRad9-hHus1-
hRad1 complex actively participates in an evolutionarily conserved DNA damage-induced 
signaling cascade.  
 
 hRad1 seems to possess exonuclease activity. The presence of a putative DNA-
metabolizing protein in the multimolecular checkpoint complex, coupled with genetic data that 
place spRad9, spHus1, and spRad1 early in the response pathway of checkpoint activation 
suggests that the complex may function as a sensor that scans the genome for damaged DNA. 
Once damaged DNA is detected, this complex may initiate endonucleolytic processing of the 
lesions and trigger interactions with downstream signaling elements, or may link unknown 
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damage recognition components to downstream signal-transducing pathways that include the 
ATM kinase, which is implicated in actively enforcing cell cycle arrest after DNA damage.  
 
 Potential goals of checkpoint research include the implementation of screening tests to 
identify familial cancer predisposition and treatment of checkpoint gene defects by gene 
transfer. Another aim of checkpoint research is the development of checkpoint-based cancer 
therapy. More than 50% of all human malignant tumors contain mutated p53, and p53-
deficient tumor cells lack induction of the G1-S checkpoint in response to DNA damage. One 
emerging hypothesis is that selective inhibitors of the compensating G2-M checkpoint would 
preferentially radiosensitize p53-deficient tumor cells. Thus, the investigation of checkpoint 
function in humans provides further targets for chemotherapeutic agents and will help to 
design future strategies in cancer therapy.  
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6 Zusammenfassung 
Um DNA-Mutationen und in der Folge die Krebsentstehung beim Menschen zu 
verhindern, besitzen Zellen Schutzmechanismen wie DNA-Reparatur und Zellzyklus-
Checkpoints. Die Untersuchung hereditärer Instabilitätssyndrome wie Xeroderma 
pigmentosum oder Nijmegen Breakage Syndrome hat ergeben, dass Defekte in DNA-
Reparaturgenen die Karzinogenese beschleunigen und eine erbliche Krebsprädisposition 
bedingen können. Neben den DNA-Reparaturmechanismen gewinnen Checkpoints in der 
Erforschung der Krebsentstehung und in der Krebstherapie zunehmend an Bedeutung.  
 
Checkpoints sind Signalkaskaden, die als Folge eines DNA-Schadens aktiviert werden 
und den Zellzyklus an definierten Positionen verlangsamen oder stoppen. Dadurch wird Zeit 
für die Koordination der DNA-Reparatur gewonnen und so die Integrität des Genoms 
gewahrt. Während die Bedeutung des p53-abhängigen G1-S-Checkpoints mittlerweile 
unumstritten ist, weiß man bis heute wenig über andere Checkpoints beim Menschen wie zum 
Beispiel den G2-M- oder den S-Phase-Progressions-Checkpoint. Die Untersuchung des 
Instabilitätssyndroms Ataxia teleangiectatica (AT) hat gezeigt, dass γ-bestrahlte AT-Zellen 
nicht in der Lage sind, verschiedene Checkpoints zu induzieren. Diese Beobachtung ließ die 
Vermutung aufkommen, dass ein Checkpoint-Gendefekt für die Zunahme der Malignom-
Inzidenz bei AT-Patienten ursächlich ist. Das verantwortliche Gen (ATM) ist ein Homolog des 
Checkpoint-Kinase-Gens sprad3 der Spalthefe Schizosaccharomyces pombe (S. pombe). In S. 
pombe reguliert spRad3 die G2-M-Checkpoint-Aktivierung als zelluläre Antwort auf 
geschädigte DNA. Defekte im sprad3-Gen, ebenso wie Defekte im ATM-Gen, führen zu einer 
gesteigerten Empfindlichkeit des Organismus gegenüber Karzinogenen, was eine evolutionäre 
Konservierung der Checkpoint-Signalkaskaden von der Hefe zum Menschen sowie eine 
mögliche Rolle des G2-M-Checkpoints in der Krebsentstehung nahe legt. 
 
Die Entdeckung G2-M-Checkpoint-defizienter Hefemutanten ermöglichte die 
Klonierung weiterer Hefe-Checkpoint-Gene und die Identifikation ihrer humanen Homologe. 
Diese neue Gruppe menschlicher Gene beinhaltet Homologe von sprad9 (hRAD9), sphus1 
(hHUS1) und sprad1 (hRAD1). In der Spalthefe S. pombe sind die Genprodukte von sprad9, 
sphus1 und sprad1 für die Aktivierung der Kinase spRad3 notwendig, und Defekte in einem 
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oder mehreren dieser Gene verursachen eine erhöhte Sensibilität gegenüber Mutagenen. 
Gendefekte in den humanen Homologen der rad-Gene könnten, wie im Falle von p53 oder 
Ataxia teleangiectatica, einen Anstieg der Mutationsrate bedingen und für eine erbliche 
Krebsprädisposition verantwortlich sein. 
 
In Anbetracht dieser potenziellen Bedeutung menschlicher rad-Gene im Prozess der 
Karzinogenese wurde hier eine zelluläre und molekulare Analyse der neuen humanen 
Checkpoint-Proteine hRad9, hHus1 und hRad1 in der Leukämie-Zelllinie K562 und in 
menschlichen Keratinozyten unternommen. Mit Hilfe spezifischer Antikörper gegen humanes 
Rad9, Hus1 und Rad1 konnte in Ko-Immunopräzipitations- und Western-Blot-Experimenten 
demonstriert werden, dass sich hRad9, hHus1 und hRad1 zu einem biochemischen Komplex 
ähnlich dem in Spalthefe bekannten spRad9-spHus1-spRad1-Komplex verbinden. 
 
Um ein Modellsystem zu schaffen, in dem die Funktionen der Checkpoint-Proteine 
analysiert werden können, wurden Epitop-markierte Expressionsvektoren für hRad9, hHus1 
und hRad1 generiert. Diese wurden durch Elektroporation in K562-Zellen transfiziert, was zur 
transienten Expression der Epitop-markierten Proteine führte. Durch simultane Expression von 
hRad9, hHus1 und hRad1 konnte der Nachweis erbracht werden, dass die Epitop-markierten 
Checkpoint-Proteine hRad9, hHus1 und hRad1 die Komplexbildung der endogenen Proteine 
rekapitulieren. Anhand von Immunopräzipitations-Experimenten mit Lysaten hRad9 
überexprimierender Zellen wurde belegt, dass hRad9 komplexen post-translationellen 
Modifikationen unterzogen wird. Die Ko-Expression von hRad9 mit hRad1 und hHus1 
resultierte in einem Anstieg der Menge von hRad9 in seiner modifizierten Form, was 
suggeriert, dass hRad1 und hHus1 entweder die Produktion von stark modifiziertem hRad9 
fördern oder aber die modifizierte Form von hRad9 stabilisieren. 
 
Für die Hefe-Checkpoints konnte ein direkter Zusammenhang zwischen der 
Phosphorylierung von Checkpoint-Proteinen und der Aktivierung der Checkpoint-
Signalkaskaden bewiesen werden. In dieser Studie konnte aufgedeckt werden, dass hRad9 in γ-
bestrahlten Zellen phosphoryliert wird und dass phosphoryliertes hRad9 ebenso mit hRad1 und 
hHus1 interagiert. Dies weist darauf hin, dass der hRad9-hHus1-hRad1-Komplex ein aktives 
Element einer Checkpoint-Signalkaskade ist, die durch DNA-Schäden aktiviert wird.  
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Einige Studien lieferten Hinweise dafür, dass hRad1 Exonuklease-Aktivität besitzt. Die 
Tatsache, dass ein potenziell DNA-metabolisierendes Protein Bestandteil eines Checkpoint-
Proteinkomplexes ist, in Verbindung mit den Ergebnissen genetischer Untersuchungen der 
Spalthefe S. pombe, die spRad9, spHus1 und spRad1 früh in den Prozess der zellulären 
Antwort auf geschädigte DNA einordnen, deutet darauf hin, dass der Komplex als Sensor für 
DNA-Schäden dienen könnte. Nach der Entdeckung geschädigter DNA könnte der 
Proteinkomplex die endonukleolytische Prozessierung der DNA-Läsionen initiieren und 
Interaktionen mit stromabwärts in der Signalkaskade fungierenden Elementen vermitteln. 
Alternativ könnte der Komplex bisher unbekannte Sensoren für geschädigte DNA an die 
Funktion der stromabwärts agierenden ATM-Kinase koppeln, welche aktiv den Zellzyklus 
anhält, sobald DNA geschädigt wird.  
 
Mögliche Ziele der Checkpoint-Forschung sind beispielsweise die Behandlung von 
Checkpoint-Genmutationen mittels Gentransfer, der Einsatz von Screening-Tests zur 
Identifikation familiär prädisponierter Personengruppen oder die Entwicklung Checkpoint-
basierter Krebstherapien. Dabei macht man sich zu Nutze, dass mehr als 50 % aller malignen 
Tumore auf Grund einer p53-Mutation nicht in der Lage sind, auf DNA-Schäden mit der 
Induktion des G1-S-Checkpoints zu reagieren. Selektive Inhibitoren des den G1-S-Checkpoint 
kompensierenden G2-M-Checkpoints bewirken eine gegenüber gesundem Gewebe gesteigerte 
Strahlen- und Chemosensibilität der Tumorzellen. So eröffnet die Checkpoint-Forschung durch 
die Entdeckung zusätzlicher molekularer Angriffspunkte für Chemotherapeutika neue 
Möglichkeiten in der Konzeption künftiger Krebstherapien. 
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8 Abbreviations 
α    Anti 
APC    (familial) Adenomatous polyposis coli 
APS    Ammonium polysulfide 
AT    Ataxia telangiectasia 
ATM    Ataxia telangiectasia mutated 
ATR    Ataxia telangiectasia related 
AU1    Australia antigen 1 
BRCA1   Breast cancer 1 
BSA     Bovine serum albumin 
CaCl    Calcium chloride 
CDK    Cyclin-dependent kinase 
Chk1    Checkpoint kinase 1  
CIP     Calf intestinal phosphatase 
CsCl    Cesium chloride 
DCC    Deleted in colon carcinoma 
EDTA    Ethylenediaminetetraacetic acid 
FCS    Fetal calf serum 
FLAG    Flagellar antigen 
G1    Gap 1 (in the cell cycle) 
G1-S    Cell cycle boundary from G1 to S-phase 
G2    Gap 2 (in the cell cycle) 
G2-M    Cell cycle boundary from G2 to M-phase 
GAA    Glacial acetic acid 
GFP    Green fluorescent protein 
GSH    Glutathione S-agarose 
GST    Glutathione S-transferase 
GTE    Glucose TRIS-EDTA 
Gy    Gray 
h    Human 
HA    Hemagglutinin 
HCl    Hydrochloric acid 
HEPES   N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic acid 
HRP    Horseradish peroxidase 
Hus    Hydroxyurea-sensitive 
Ig    Immuno-globulin 
IR    Ionizing radiation 
KAc     Potassium acetate  
KCl    Potassium chloride 
K2HPO4   Potassium phosphate 
K-ras    Kirsten murine sarcoma virus oncogene causing rat’s sarcoma 
LB    Luria broth 
LE Agarose   Low electroendosmosis agarose 
LF    Li-Fraumeni 
M    Mitosis 
mAB    Monoclonal antibody 
MgCl2    Magnesium chloride 
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Microcystin-LR  Microcystin with leucin (L) and arginin (R) residues 
NaAc    Sodium acetate 
NaCl    Sodium chloride 
NaF    Sodium fluoride 
Na2HPO4   Sodium phosphate 
NaN3    Sodium azide 
NaOH    Sodium hydroxide  
Na3VO4   Sodium orthovanadate  
NBS    Nijmegen breakage syndrome 
OD    Optic density 
p    Protein 
p53-    p53-deficiency 
PAGE    Polyacrylamide gel electrophoresis 
PCNA    Proliferating cell nuclear antigen 
PCR    Polymerase chain reaction 
PI-3    Phosphatidylinositol 3 
PIK    Phosphatidylinositol 3-kinase 
PIKK    Phosphatidylinositol 3-kinase-related kinase 
PK    Protein kinase 
PI    Propidium iodide 
rad    Radiosensitive 
RFC    Replication factor C 
S    Synthesis 
S. Schizosaccharomyces 
sc    Saccharomyces cerevisiae 
sp    Schizosaccharomyces pombe 
SDS    Sodium dodecyl sulfate 
TAE    TRIS-acetate-EDTA 
TB    Terrific broth 
TBS    TRIS-buffered saline  
TE    TRIS-EDTA 
TEMED   Tetramethyl-1,2-diaminoethane 
TP    Tumor protein 
TRIS    Tris hydroxymethylaminoethane buffer 
TWEEN 20   Polyoxyethylene sorbitan monolaureate 
UCN-01   7-hydroxystaurosporine 
um    Ustilago maydis 
UV    Ultraviolet 
XP    Xeroderma pigmentosum 
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